0001642159 true S-1/A P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y P5Y 0001642159 2022-01-01 2022-09-30 0001642159 dei:BusinessContactMember 2022-01-01 2022-09-30 0001642159 2021-12-31 0001642159 2020-12-31 0001642159 2022-09-30 0001642159 2021-01-01 2021-12-31 0001642159 2020-01-01 2020-12-31 0001642159 2021-01-01 2021-09-30 0001642159 2022-07-01 2022-09-30 0001642159 2021-07-01 2021-09-30 0001642159 us-gaap:CommonStockMember 2019-12-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001642159 us-gaap:RetainedEarningsMember 2019-12-31 0001642159 2019-12-31 0001642159 us-gaap:CommonStockMember 2020-12-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001642159 us-gaap:RetainedEarningsMember 2020-12-31 0001642159 us-gaap:CommonStockMember 2021-03-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001642159 us-gaap:RetainedEarningsMember 2021-03-31 0001642159 2021-03-31 0001642159 us-gaap:CommonStockMember 2021-06-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001642159 us-gaap:RetainedEarningsMember 2021-06-30 0001642159 2021-06-30 0001642159 us-gaap:CommonStockMember 2021-12-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001642159 us-gaap:RetainedEarningsMember 2021-12-31 0001642159 us-gaap:CommonStockMember 2022-03-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001642159 us-gaap:RetainedEarningsMember 2022-03-31 0001642159 2022-03-31 0001642159 us-gaap:CommonStockMember 2022-06-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001642159 us-gaap:RetainedEarningsMember 2022-06-30 0001642159 2022-06-30 0001642159 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001642159 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001642159 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001642159 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001642159 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001642159 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001642159 2021-01-01 2021-03-31 0001642159 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001642159 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001642159 2021-04-01 2021-06-30 0001642159 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001642159 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001642159 2022-01-01 2022-03-31 0001642159 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001642159 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001642159 2022-04-01 2022-06-30 0001642159 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001642159 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001642159 us-gaap:CommonStockMember 2022-09-30 0001642159 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001642159 us-gaap:RetainedEarningsMember 2022-09-30 0001642159 2021-09-30 0001642159 SIGN:ShareExchangeAgreementMember SIGN:SigynStockholderMember 2020-10-19 0001642159 SIGN:ShareExchangeAgreementMember 2020-10-18 2020-10-19 0001642159 SIGN:SigynStockholdersMember SIGN:ShareExchangeAgreementMember 2020-10-19 0001642159 us-gaap:SubsequentEventMember 2022-03-14 0001642159 SIGN:NonAffiliateShareholdersMember 2022-03-14 0001642159 SIGN:ShareExchangeAgreementMember SIGN:IssuedAndOutstandingSharesMember 2020-10-19 0001642159 2022-08-15 0001642159 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001642159 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001642159 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001642159 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2021-12-31 0001642159 us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001642159 us-gaap:OfficeEquipmentMember 2021-12-31 0001642159 us-gaap:OfficeEquipmentMember 2020-12-31 0001642159 us-gaap:ComputerEquipmentMember 2021-01-01 2021-12-31 0001642159 us-gaap:ComputerEquipmentMember 2021-12-31 0001642159 us-gaap:ComputerEquipmentMember 2020-12-31 0001642159 us-gaap:OfficeEquipmentMember 2022-01-01 2022-09-30 0001642159 us-gaap:OfficeEquipmentMember 2022-09-30 0001642159 us-gaap:ComputerEquipmentMember 2022-01-01 2022-09-30 0001642159 us-gaap:ComputerEquipmentMember 2022-09-30 0001642159 us-gaap:TrademarksMember 2021-01-01 2021-12-31 0001642159 us-gaap:TrademarksMember 2021-12-31 0001642159 us-gaap:TrademarksMember 2020-12-31 0001642159 SIGN:WebsiteMember 2021-01-01 2021-12-31 0001642159 SIGN:WebsiteMember 2021-12-31 0001642159 SIGN:WebsiteMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2020-01-25 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2020-06-20 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2020-09-15 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember 2021-10-27 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2020-01-26 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2020-06-21 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2020-09-16 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:OsherCapitalPartnersLLCMember 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:OsherCapitalPartnersLLCMember 2021-10-27 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2022-03-22 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2022-04-28 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2022-04-27 2022-04-28 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2022-05-10 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2022-05-09 2022-05-10 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2022-06-01 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2022-05-31 2022-06-01 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2022-06-22 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2022-06-21 2022-06-22 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2022-07-31 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2022-07-30 2022-07-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2022-08-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2022-08-01 2022-08-31 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2022-09-09 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2022-09-08 2022-09-09 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2022-09-20 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2022-09-19 2022-09-20 0001642159 SIGN:ConvertiblePromissoryNoteNineMember SIGN:OsherCapitalPartnersLLCMember 2022-07-01 2022-07-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2022-01-01 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2022-01-01 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2022-01-01 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2022-06-30 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteOneMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteFourMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteSixMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteEightMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteNineMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTenMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-01-26 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-19 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-21 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:PreviousNoteholderOneMember 2020-06-21 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-06-21 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementTwoMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-18 2021-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-21 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-15 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-09-15 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-27 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-06-21 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementTwoMember 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:PreviousNoteholderOneMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:PreviousNoteholderOneMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-12-02 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:PreviousNoteholderOneMember 2020-12-02 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember SIGN:SecuritiesPurchaseAgreementMember 2020-08-16 2020-08-18 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-08-18 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember SIGN:SecuritiesPurchaseAgreementMember 2020-08-18 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-10-28 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember us-gaap:CommonStockMember 2020-10-28 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderTwoMember us-gaap:CommonStockMember 2021-02-19 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderThreeMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-16 2020-09-18 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-18 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderThreeMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-18 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderThreeMember SIGN:AmendedConvertibleDebtAgreementTwoMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderThreeMember SIGN:AmendedConvertibleDebtAgreementTwoMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember 2020-12-02 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderThreeMember us-gaap:CommonStockMember 2020-12-02 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-19 2020-09-21 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-21 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-21 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2021-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2020-11-05 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2021-11-05 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-26 2020-09-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-28 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-28 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2021-10-18 2021-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-27 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember us-gaap:CommonStockMember 2020-10-27 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSixMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-26 2020-09-29 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-29 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSixMember SIGN:SecuritiesPurchaseAgreementMember 2020-09-29 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSixMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSixMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderFiveMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-26 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-02-09 2021-02-10 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-02-10 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSevenMember SIGN:SecuritiesPurchaseAgreementMember 2021-02-10 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSevenMember us-gaap:CommonStockMember 2021-05-10 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderEightMember SIGN:SecuritiesPurchaseAgreementMember 2021-05-04 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderEightMember SIGN:SecuritiesPurchaseAgreementMember 2021-05-01 2021-05-04 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSevenMember SIGN:SecuritiesPurchaseAgreementMember 2021-02-08 2021-02-10 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:PreviousNoteholderSevenMember 2021-02-10 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:PreviousNoteholderSevenMember us-gaap:CommonStockMember 2021-10-25 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember SIGN:OsherCapitalPartnersLLCMember 2022-09-19 2022-09-20 0001642159 SIGN:ConvertiblePromissoryNoteTwelveMember SIGN:OsherCapitalPartnersLLCMember 2022-09-20 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember SIGN:BrioCapitalMasterFundLtdMember 2022-09-08 2022-09-09 0001642159 SIGN:ConvertiblePromissoryNoteElevenMember SIGN:BrioCapitalMasterFundLtdMember 2022-09-09 0001642159 SIGN:ConvertiblePromissoryNoteTenMember SIGN:OsherCapitalPartnersLLCMember 2022-08-30 2022-08-31 0001642159 SIGN:ConvertiblePromissoryNoteTenMember SIGN:OsherCapitalPartnersLLCMember 2022-08-31 0001642159 SIGN:ConvertiblePromissoryNoteNineMember SIGN:OsherCapitalPartnersLLCMember 2022-07-31 0001642159 SIGN:ConvertiblePromissoryNoteEightMember SIGN:OsherCapitalPartnersLLCMember 2022-06-21 2022-06-22 0001642159 SIGN:ConvertiblePromissoryNoteEightMember SIGN:OsherCapitalPartnersLLCMember 2022-06-22 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember SIGN:OsherCapitalPartnersLLCMember 2022-05-31 2022-06-01 0001642159 SIGN:ConvertiblePromissoryNoteSevenMember SIGN:OsherCapitalPartnersLLCMember 2022-06-01 0001642159 SIGN:ConvertiblePromissoryNoteSixMember SIGN:BrioCapitalMasterFundLtdMember 2022-05-09 2022-05-10 0001642159 SIGN:ConvertiblePromissoryNoteSixMember SIGN:BrioCapitalMasterFundLtdMember 2022-05-10 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember SIGN:OsherCapitalPartnersLLCMember 2022-04-27 2022-04-28 0001642159 SIGN:ConvertiblePromissoryNoteFiveMember SIGN:OsherCapitalPartnersLLCMember 2022-04-28 0001642159 SIGN:ConvertiblePromissoryNoteFourMember SIGN:OsherCapitalPartnersLLCMember 2022-03-22 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteFourMember SIGN:OsherCapitalPartnersLLCMember 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteFourMember SIGN:BrioCapitalMasterFundLtdMember 2022-03-22 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteFourMember SIGN:BrioCapitalMasterFundLtdMember 2022-03-23 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-16 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:AmendedConvertibleDebtAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-09-17 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:AmendedConvertibleDebtAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-19 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:AmendedConvertibleDebtAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:AmendedConvertibleDebtAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-27 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteThreeMember SIGN:AmendedConvertibleDebtAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-28 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-06-23 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementTwoMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-10-18 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-19 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-10-20 0001642159 SIGN:ConvertiblePromissoryNoteTwoMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:SecuritiesPurchaseAgreementMember SIGN:OsherCapitalPartnersLLCMember 2020-01-27 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:AmendedConvertibleDebtAgreementMember 2020-01-27 2020-01-28 0001642159 SIGN:ConvertiblePromissoryNoteOneMember SIGN:OsherCapitalPartnersLLCMember SIGN:SecuritiesPurchaseAgreementMember 2020-10-20 0001642159 SIGN:OsherCapitalPartnersLLCMember 2021-10-27 2021-10-28 0001642159 SIGN:OsherCapitalPartnersLLCMember 2021-10-28 0001642159 SIGN:MarketingConsultingAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-25 0001642159 SIGN:MarketingConsultingAgreementMember SIGN:OsherCapitalPartnersLLCMember 2021-10-24 2021-10-25 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:SecuritiesPurchaseAgreementMember 2021-10-18 2021-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:SecuritiesPurchaseAgreementMember 2021-10-20 0001642159 SIGN:ConvertiblePromissoryNoteMember SIGN:SecuritiesPurchaseAgreementMember 2021-10-08 2021-10-20 0001642159 2021-10-12 2021-10-14 0001642159 2021-07-12 2021-07-14 0001642159 2021-05-01 2021-05-10 0001642159 2021-04-01 2021-04-30 0001642159 2021-04-30 0001642159 2021-05-10 0001642159 2021-04-01 2021-04-14 0001642159 SIGN:PreviousNoteholderMember 2021-02-19 0001642159 2021-01-12 2021-01-14 0001642159 SIGN:ThirdPartiesMember 2020-01-01 2020-12-31 0001642159 2020-10-18 2020-10-19 0001642159 SIGN:ConvertiblePromissoryNoteMember 2021-10-18 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteMember 2021-10-22 0001642159 SIGN:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0001642159 SIGN:ConvertiblePromissoryNoteMember 2020-01-01 2020-12-31 0001642159 SIGN:ConvertiblePromissoryNoteMember 2022-07-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteMember 2022-01-01 2022-09-30 0001642159 SIGN:ConvertiblePromissoryNoteMember 2021-07-01 2021-09-30 0001642159 SIGN:ConvertiblePromissoryNoteMember 2021-01-01 2021-09-30 0001642159 2021-05-01 2021-05-27 0001642159 SIGN:ASC842Member 2021-06-15 0001642159 2021-05-26 2021-05-27 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrJoyceMember 2021-01-01 2021-12-31 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrJoyceMember 2020-12-31 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrJoyceMember 2020-01-01 2020-12-31 0001642159 SIGN:EmploymentAgreementsMember SIGN:ChiefTechnologyOfficerMember 2021-01-01 2021-12-31 0001642159 SIGN:EmploymentAgreementsMember SIGN:ChiefTechnologyOfficerMember 2020-01-01 2020-12-31 0001642159 SIGN:CEOAndCTOMember 2021-07-20 2021-07-21 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrFerrellMember 2022-03-08 2022-03-09 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrFerrellMember 2022-07-01 2022-09-30 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrFerrellMember 2021-07-01 2021-09-30 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrFerrellMember 2022-01-01 2022-09-30 0001642159 SIGN:EmploymentAgreementsMember SIGN:MrFerrellMember 2021-01-01 2021-09-30 0001642159 us-gaap:SubsequentEventMember 2022-03-08 2022-03-09 0001642159 us-gaap:SubsequentEventMember 2022-03-09 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember 2022-03-22 2022-03-23 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember 2022-03-23 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:BrioCapitalMasterFundLtdMember 2022-03-22 2022-03-23 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:BrioCapitalMasterFundLtdMember 2022-03-23 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-10-20 2022-10-20 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-10-20 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:BrioCapitalMasterFundLtdMember 2022-11-09 2022-11-09 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:BrioCapitalMasterFundLtdMember us-gaap:SubsequentEventMember 2022-11-09 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:BrioCapitalMasterFundLtdMember us-gaap:SubsequentEventMember 2022-11-09 2022-11-09 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-11-14 2022-11-14 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-11-14 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-11-21 2022-11-21 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-11-21 0001642159 SIGN:OriginalIssueDiscountSeniorDebentureNoteMember SIGN:OsherCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2022-11-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

AS FILED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 22, 2022

 

Registration No. 333-265782

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

AMENDMENT NO. 3 TO

FORM S-1

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

SIGYN THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)

 

Delaware   3841   47-2573116
(State or other jurisdiction of
incorporation or organization)
 

(Primary Standard Industrial

Classification Code)

 

(I.R.S. Employer

Identification No.)

 

2468 Historic Decatur Road

Suite 140

San Diego, California 92106

Telephone: (619) 353-0800

(Address and Telephone Number of Registrant’s Principal
Executive Offices and Principal Place of Business)

 

VCorp Services

18 Lafayette Place

Woodmere, NY 11598

Telephone: (845) 425-0077

(Name, Address, and Telephone Number for Agent of Service)

 

Copies to:

 

Jolie Kahn, Esq.   Patrick J. Egan, Esq.
12 E. 49th Street, 11th Floor   Leslie Marlow, Esq.
New York, NY 10017   Hank Gracin, Esq.
Telephone: (516) 217-6379   Blank Rome LLP
Fax: (866) 705-3071   1271 Avenue of the Americas
    New York, NY 10020
    Phone: (212) 885-5000
    Fax: (212) 885-5001

 

Approximate date of commencement of proposed sale to the public: As soon as practicable on or after the effective date of this registration statement.

 

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, please check the following box: ☒

 

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated Filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Commission acting pursuant to said Section 8(a) may determine.

 

 

 

 
 

 

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED DECEMBER 22, 2022

 

Sigyn Therapeutics, Inc.

 


 

Class A Units

Each Class A Unit Consisting of

One Share of Common Stock and

One Series A Warrant to Purchase One Share of Common Stock

Class B Units

Each Class B Unit Consisting of __ Shares of Series B Preferred Stock and One Series A Warrant to

Purchase One Share of Common Stock

 

This is a firm commitment public offering of ____ Class A Units (“Class A Units”), with each Class A Unit consisting of one share of our common stock, par value $0.001 per share, and one Series A Warrant to purchase one share our common stock (and the shares issuable from time to time upon exercise of the Series A Warrants) pursuant to this prospectus based on an assumed offer price of $____ for each Class A Unit. Each Series A Warrant will have an exercise price of $____ (assumed) per share, will be exercisable upon issuance and will expire five years from issuance. We expect the public offering price will be $______ per Class A Unit.

 

The Class A Units have no stand-alone rights, will not be certificated or issued as stand-alone securities and there will be no trading market for the Class A Units. The shares of common stock and the Series A Warrants comprising the Class A Units will separate immediately upon completion of this offering and prior to any trading of the common stock and Series A Warrants.

 

We are also offering to those purchasers, whose purchase at least $250,000 of Class A Units or whose purchase of Class A Units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of the number of Class A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock or who would purchase at least $250,000 of Class A Units, a unit consisting of one share of Series B convertible preferred stock, par value $.001 per share (“Series B Preferred Stock”), convertible at any time at the holder’s option into a number of shares of common stock equal to $5,000 divided by $_____, the public offering price per Class A Unit (the “Conversion Price”), and warrants to purchase a number of shares of common stock equal to the number of shares of common stock issuable upon conversion of one share of Series B Preferred Stock (“Class B Unit”) at a public offering price of $5,000 per Class B unit. The Series B preferred shares contain price protection so that if any offering is made of our Common Stock or common stock equivalents at a price per share lower than the offering price per share in this offering, the conversion price of the Series B Preferred shares will automatically be reduced to the lower price per share. The warrants included in the Class B Units will have the same terms as the warrants included in the Class A Units. For each Class B Unit we sell, the number of Class A Units we are offering will be decreased on a dollar-for-dollar basis. Because we will issue a Series A Warrant as part of the Class A Unit or Class B Unit, the number of Series A Warrants sold in this offering will not change as a result of the change in the mix of Class A Units and Class B Units.

 

Our common stock trades on the OTCQB® Venture Market under the symbol “SIGY”. On December 22, 2022, the last report sale price of our common stock on the OTCQB® Venture Market was $_____. Prior to this offering, there has been no public market for our Class A Units or our Series A Warrants. We plan to apply  to have our shares of common stock listed on the Nasdaq Capital Market under the symbol “SIGY”. No assurance can be given that our application will be approved or that the trading price of our common stock on the OTCQB® Venture Market will be indicative of the prices of our common stock if our common stock were traded on the Nasdaq Capital Market.  If, for whatever reason, Nasdaq does not confirm the listing of our common stock on Nasdaq prior to the pricing of the offering, we will not be able to consummate and will terminate this offering. There is no established trading market for the Series A Warrants or the Series B Preferred Stock. In addition, we do not intend to apply for the listing of the Series A Warrants or the Series B Preferred on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Series A Warrants and the Series B Preferred Stock will be limited.

 

The number of Class A Units and Class B Unit offered in this prospectus and all other applicable information has been determined based on an assumed public offering price of $_____ per Class A Unit and $___ per Class B Unit, which is based on the last reported sales price of our common stock of $           on             , 2022. The actual public offering price of the Class A Units and Class B Units will be determined between the underwriters and us at the time of pricing, considering our historical performance and capital structure, prevailing market conditions, and overall assessment of our business, and may be at a discount to the current market price. Therefore, the assumed public offering price per Class A Unit and Class B Unit used throughout this prospectus may not be indicative of the actual public offering price for the Class A Units and Class B Units. See “Determination of Offering Price” for additional information.

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

We are an “emerging growth company” under the federal securities laws and may elect to comply with certain reduced public company reporting requirements for future filings.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

    Class A Unit   Class B Unit   Total  
Public offering price   $         $        $       
Underwriting discounts and commissions(1)   $     $     $    
Proceeds to us, before expenses (2)   $     $     $    

 

(1)We have also agreed to issue warrants to purchase shares of our common stock to the representative of underwriters and to reimburse the representative of the underwriters for certain expenses. See “Underwriting” for additional information regarding total underwriter compensation.
(2)The amount of offering proceeds to us presented in this table does not give effect to any exercise of the: (i) over-allotment option (if any) we have granted to the representative of the underwriters as described below and (ii) warrants being issued to the representative of the underwriters in this offering. The public offering price and underwriting discount corresponds to (i) in respect of the Class A Units (a) a public offering price per share of common stock of $__ and (b) a public offering price per Series A Warrant of $__, and (ii) in respect of the Class B Units (a) a public offering price per share of Series B Preferred Stock of $__ and (ii) a public offering price per Series A Warrant of $_____.

 

We have granted a 45-day option to the underwriters, exercisable one or more times in whole or in part, to purchase up to an additional ____ shares of common stock and/or __ shares of Series B Preferred Stock and/or  additional Series A Warrants (having the same terms as the Series A Warrants included in the Class A Units in the offering) from us in any combination thereof at the public offering price per share of common stock equal to the public offering price per Class A Unit minus $0.01 per share and $0.01 per Series A Warrant, respectively, less the underwriting discounts payable by us, solely to cover over-allotments, if any.

 

The underwriters expect to deliver the securities to purchasers in the offering on or about               , 2022.

 

 

The date of this prospectus is           , 2022

 

 
 

 

Table of Contents

 

  Page
   
Prospectus Summary 1
The Offering 3
Summary Financial Data 5
Risk Factors 6
Cautionary Note Regarding Forward-Looking-Statements 19
Use of Proceeds 21
Determination of Offering Price 22
Market for our Common Stock and Related Stockholder Matters 22
Dividend Policy 22
Capitalization 23
Dilution 25
Management’s Discussion and Analysis of Financial Condition and Results of Operation 25
Description of Business 44
Description of Property 52
Directors, Executive Officers, Promoters, and Control Persons 52
Executive Compensation 56
Security Ownership of Certain Beneficial Owners and Management 59
Underwriting 60
Certain Relationships and Related Transactions 65
Description of Securities 69
Shares Eligible for Future Sales 73
Legal Matters 73
Experts 74
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 74
Where You Can Find More Information 74
Financial Statements F-1
Other Expenses of Issuance and Distribution II-1
Recent Sale of Unregistered Securities II-2
Exhibits II-9
Undertakings II-11
Signatures II-12

 

You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus.

 

 
 

 

PROSPECTUS SUMMARY

 

Except as otherwise indicated, as used in this prospectus, references to the “Company,” “we,” “us,” or “our” refer to Sigyn Therapeutics, Inc.

 

The following summary highlights selected information contained in this prospectus, and it may not contain all of the information that is important to you. Before making an investment decision, you should read the entire prospectus carefully, including “Risk Factors” and our financial statements and related notes, included elsewhere in, or incorporated by reference into, this prospectus.

 

Our Company

 

Sigyn Therapeutics, Inc. (“Sigyn”, the “Company” “we,” “us,” or “our”) is a development-stage company focused on addressing unmet needs in global health. Sigyn Therapy™ is a broad-spectrum blood purification technology designed to reduce the presence of viral pathogens, bacterial toxins, and inflammatory mediators from the bloodstream.

 

Candidate treatment indications for Sigyn Therapy include endotoxemia and inflammation in End-Stage Renal Disease (ESRD) dialysis patients, Sepsis (leading cause of hospital deaths worldwide1), Community Acquired Pneumonia (a leading cause of death among infectious diseases2) and Emerging Bioterror and Pandemic threats.

 

Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have filed patent and trademark submissions related to a therapeutic system to enhance the delivery of cancer chemotherapy and reduce its toxicity. At present, we have no market approved medical products.

 

1Global, regional and national sepsis incidence and mortality The Journal Lancet, January 2020  

 

2The American Thoracic Society – Pneumonia Facts 2019

 

Risks and Challenges That We Face

 

An investment in our securities involves a high degree of risk. You should carefully consider the risks summarized below and the other risks that are discussed more fully in the “Risk Factors” section of this prospectus immediately following this prospectus summary. These risks include, but are not limited to, the following:

 

  Demand and market acceptance of our product offerings may be considerably less than what we currently anticipate.
     
  We may be unable to increase revenues in the manner in which we anticipate and generate profitability.
     
  We may face challenges in successfully completing U.S. Food and Drug Administration (“FDA”) testing requirements.
     
  We may not be able to meet increased and changing regulatory requirements.
     
 

We believe the FDA will classify our lead product candidate to be a significant risk Class III device, which would require extensive pre-clinical and clinical studies to be conducted along with the submission of a Pre-Market Approval (PMA) application prior to market clearance consideration by FDA.

     
  We will need to raise additional capital to fully commercialize our products.
     
  Some of our target products may face an uncertain regulatory environment.
     
  We may be unable to expand operations and manage growth.
     
  We may be unable to retain key members of our management and development teams and to recruit additional qualified personnel.
     
 

We face competition from companies that have greater resources than we do and we may not be able to effectively compete against these companies.

     
  We face risks as a result of the ongoing COVID-19 pandemic.
     
  As stated in their audit opinion for our audited financials for the year ended December 31, 2021, our auditors believe that we may not be able to continue as a going concern.
     
  Since inception, our primary focus has been directed toward the advancement of Sigyn Therapy. As of September 30, 2022, we have an accumulated deficit of $6.3 million and a working capital deficit of $1.8 million.

 

1
 

 

Implications of Being an Emerging Growth Company

 

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not “emerging growth companies” including, but not limited to:

 

  being permitted to present only two years of audited financial statements and only two years of related disclosure in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this prospectus;
     
  being permitted to provide less extensive narrative disclosure than other public companies including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements;
     
  being permitted to utilize exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved;
     
  being permitted to defer complying with certain changes in accounting standards; and
     
  being permitted to use test-the-waters communications with qualified institutional buyers and institutional accredited investors.

 

We intend to take advantage of these and other exemptions available to “emerging growth companies.” We could remain an “emerging growth company” until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion, (c) the last day of our fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

 

The JOBS Act permits an “emerging growth company” like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. This means that an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards.

 

Available Information

 

We file various reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which are available through the SEC’s electronic data gathering, analysis and retrieval system (“EDGAR”) by accessing the SEC’s home page (http://www.sec.gov).

 

Corporate Information

 

On October 19, 2020, Sigyn Therapeutics, Inc, a Delaware corporation (the “Registrant”) formerly known as Reign Resources Corporation, completed a Share Exchange Agreement (the “Agreement”) with Sigyn Therapeutics, Inc., a private entity incorporated in the State of Delaware on October 19, 2019. Our mailing address is currently 2468 Historic Decatur Road., Suite 140, San Diego, California, 92106. Our telephone number is (619) 353-0800.

 

2
 

 

THE OFFERING

 

Class A Units offered by us:

 

We are offering Class A Units. Each Class A Unit consists of one share of our common stock and a Series A Warrant to purchase one share of our common stock (together with the shares of common stock underlying such warrants). The Class A Units will not be certificated or issued in stand-alone form. The shares of our common stock and the Series A Warrants comprising the Class A Units are immediately separable upon issuance and will be issued separately in this offering.

     
Assumed Offering price:   $[__] per Class A Unit
     
Class B Units offered by us:   We are also offering to those purchasers, who purchase at least $250,000 of Class A Units or whose purchase of Class A Units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of the number of Class A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock, or who would purchase at least $250,000 of Class A Units, Class B Units. Each Class B Unit will consist of one share of Series B Preferred Stock convertible into a number of shares of common stock equal to $5,000 divided by $____, the public offering price per Class A Unit (the “Conversion Price”), and warrants to purchase a number of shares of common stock equal to the number of shares of common stock issuable upon conversion of one share of Series B Preferred Stock (together with the shares of common stock underlying such shares of Series B Preferred Stock and such warrants). The Class B Units are immediately separable into their components upon closing of the offering contemplated hereby. For each Class B Unit we sell, the number of Class A Units we are offering will be decreased on a dollar-for-dollar basis. Because we will issue a warrant as part of each Unit, the number of warrants sold in this offering will not change as a result of a change in the mix of the Units sold.
     
Offering price per Class B Unit:   $
     
Description of Series B Preferred Stock:  

Each share of Series B Preferred Stock is convertible at any time at the holder’s option into a number of shares of common stock equal to $5,000 divided by the Conversion Price. Notwithstanding the foregoing, we shall not effect any conversion of Series B Preferred Stock, with certain exceptions, to the extent that, after giving effect to an attempted conversion, the holder of shares of Series B Preferred Stock (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of our common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%)  of the shares of our common stock then outstanding after giving effect to such exercise. The Series B Preferred Stock does not generally have any voting rights. For additional information, see “Description of Securities—Series B Preferred Stock” in this prospectus.

     
Number of shares of common stock outstanding after the offering:(1)   _______ shares of common stock
     
Market for the common stock:   Our common stock trades on the OTCQB® Venture Market under the symbol “SIGY”. On December 7, 2022, the last reported sale price for our common stock was $0.25 per share. Prior to this offering, there has been a limited market for our common stock. While our common stock trades on the OTCQB® Venture Market, there has been negligible trading volume.
     
    There is no assurance that an active trading market will develop, or, if developed, that it will be sustained. Consequently, purchasers of our common stock may find it difficult to resell the securities offered herein should the purchasers desire to do so when eligible for public resale.
     
    Our officers and directors are not purchasing securities in this offering.
     
Use of proceeds:  

We estimate that we will receive approximately $___________ in gross proceeds if we sell all of the Class A Units in the offering (based on an assumed offering price of $[__] per Class A Unit, which was the last reported sales price of our common stock on the OTCQB® Venture Market on             , 2022), and we will receive estimated net proceeds (after deducting underwriting discounts and estimated offering expenses) (assuming no exercise of the underwriter’s over-allotment option, the Series A Warrants included in the Class A Units and Class B Units or the Representatives’ Warrants offered hereby).

 
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our research and development activities, clinical trials and the regulatory review process, and the remainder for working capital and other general corporate purposes. See “Use of Proceeds” for a more detailed explanation of how the proceeds from the Offering will be used.

 

3
 

 

Over-allotment option:   We have granted a 45-day option to the representative of the underwriters to purchase up to additional shares of common stock and/or additional Series A Warrants, based on an assumed public offering price of $ per Class A Unit or $__ per Class B Unit, which was the last reported sales price of our common stock on the OTCQB® Venture Market on         , 2022 (having the same terms as the Series A Warrants included in the Class A Units and Class B Units in the offering) from us in any combination thereof at a price per share of common stock equal to the public offering price per Class A Unit and Class B Unit minus $0.01 and a price per warrant of $0.01, respectively, in each case, less the underwriting discounts payable by us, solely to cover over-allotments, if any.
     
Representative’s Warrants   The registration statement of which this prospectus is a part also registers for sale warrants (the “Representative’s Warrants”) to purchase shares of our common stock (based on an assumed offering price of $ per share, which was the last reported sales price of our common stock as quoted on the OTCQB® Venture Market on         , 2022) to Univest Securities, LLC (the “representative”), as the representative of the several underwriters, as a portion of the underwriting compensation payable to the representative in connection with this offering. The representative’s warrants will be exercisable at any time, and from time to time, in whole or in part, during the four and one half period commencing 180 days following the commencement of sales of the securities in this offering at an exercise price of $[__] (110% of the assumed public offering price of the Class A Units). Please see “Underwriting—Representative’s Warrants” for a description of these warrants.
     
Risk Factors:   See “Risk Factors‚” and the other information in this prospectus for a discussion of the factors you should consider before deciding to invest in shares of our securities.
     
Trading symbol:  

Our common stock currently trades on the OTCQB® Venture Market under the symbol “SIGY”. We plan to apply to have our shares of common stock listed on the Nasdaq Capital Market under the symbol “SIGY”. No assurance can be given that our application will be approved or that the trading prices of our common stock on the OTCQB® Venture Market will be indicative of the prices of our common stock if our common stock were traded on the Nasdaq Capital Market. If, for whatever reason, Nasdaq does not confirm the listing of our common stock on Nasdaq prior to the pricing of the offering, we will not be able to consummate and will terminate this offering.

 

There is no established trading market for the Series B Preferred Stock or the Series A Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Series B Preferred Stock or the Series A Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Series B Preferred Stock and the Series A Warrants will be limited.

     
Series A Warrants:   The exercise price of the Series A Warrants shall be 110% of the offering price of the Class A Units. The Series A Warrants have a five-year term. The Series A Warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their original issuance. The Series A Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the Series A Warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Series A Warrants under the Securities Act is not effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, the holder may, in its sole discretion, elect to exercise the Series A Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Series A Warrant. No fractional shares of common stock will be issued in connection with the exercise of a Series A Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.

 

(1) The number of shares of our common stock to be outstanding after this offering is based on shares of our common stock outstanding as December 22, 2022.
   
Unless we indicate otherwise or the context otherwise requires, all information in this prospectus:

 

  assumes no exercise by the underwriters of their option to purchase up to                  additional shares of our common stock and/or Series A Warrants from us to cover over-allotments, if any;
 

no exercise of the Series A Warrants included in the Class A Units and Class B Units;

  assumes no exercise of the Representative’s Warrants to be issued upon consummation of this offering at an exercise price equal to 110% of the initial offering price of the Class A Units;
 

assumes no shares of Series B Preferred Stock are sold in this offering;

  assumes no exercise of outstanding warrants to purchase              shares of our common stock at an exercise price of $[__]; and
  excludes shares of common stock to be reserved for future issuance under our equity incentive plan, which will be effective upon the completion of this offering.

 

To the extent we sell any Class B Units in this offering, the same aggregate number of common stock equivalents resulting from this offering would be convertible under the Series B Preferred Stock issued as part of the Class B Units.

 

4
 

 

SUMMARY FINANCIAL DATA

 

The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. The statements of operations data for the years ended December 31, 2021, and 2020 and the nine months ended September 30, 2022 and September 30, 2021, and balance sheet data as of December 31, 2021, and December 31, 2020 and September 30, 2022 and September, 2021 are derived from our audited and unaudited financial statements included elsewhere in this prospectus. The unaudited financial statements have been prepared on a basis consistent with our audited financial statements included in this prospectus and include, in our opinion, all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the financial information in those statements. 

 

The following summary financial information should be read in connection with, and is qualified by reference to, our financial statements related notes thereto and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this prospectus. Our historical results are not necessarily indicative of results to be expected in any future period.

 

Statement of Operations Data:

 

   Year ended   Year ended 
   December 31,   December 31, 
   2021   2020 
         
Operating costs and expenses          
General and administrative  $1,274,203   $497,072 
Research and development   734,014    419,362 
Total operating Expenses   2,008,217    916,434 
Loss from operations   (2,008,217)   (916,434)
           
Other expense          
Impairment of assets   536,047    - 
Interest expense   460,355    343,156 
Total other income   996,402    343,156 
Net loss   (3,004,619)   (1,259,590)
           
Net loss per share, basic and diluted  $(0.08)  $(0.17)
           
Weighted average number of shares of common stock outstanding, basic and diluted   36,396,585    7,351,272 

 

Balance Sheet Data        
         
   December 31,   December 31, 
   2021   2020 
Cash  $340,956   $84,402 
Other Current Assets  $52,075   $586,047 
Total assets  $710,259   $694,082 
Total liabilities  $974,843   $594,903 
Preferred stock  $-   $- 
Common stock  $3,730   $3,520 
Additional paid-in-capital  $3,997,445   $1,356,799 
Accumulated deficit  $(4,265,759)  $(1,261,140)
Total stockholders’ equity  $(264,584)  $694,082 

 

Statement of Operations Data:

 

   Nine Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2022   2021 
Operating costs and expenses          
Marketing expenses  $446   $164,500 
General and administrative   516,796    483,755 
Research and development   1,158,435    769,023 
Total operating Expenses   1,675,677    1,417,278 
Loss from operations   (1,675,677)   (1,417,278)
           
Other expense          
Interest expense   102    29,095 
Interest expense - debt discount   309,226    286,391 
Interest expense - original issuance costs   85,875    44,683 
Total other income   395,203    360,683 
Net loss   (2,070,880)   (1,777,447)
           
Net loss per share, basic and diluted  $(0.06)  $(0.05)
           
Weighted average number of common shares outstanding, basic and diluted   37,295,803    36,138,191 

 

Balance Sheet Data

 

   Nine Months Ended   Year Ended 
   September 30,   December 31, 
   2022   2021 
Cash  $28,123   $340,956 
Other Current Assets  $7,254   $52,075 
Total assets  $362,273   $710,259 
Total liabilities  $2,104,375   $974,843 
Preferred stock  $-   $- 
Common stock  $3,730   $3,730 
Additional paid-in-capital  $4,590,807   $3,997,445 
Accumulated deficit  $(6,336,639)  $(4,265,759)
Total stockholders’ equity (deficit)  $(1,742,102)  (264,584)

 

5
 

 

RISK FACTORS

 

You should carefully consider the risks described below before investing in our securities. Additional risks not presently known to us or that our management currently deems immaterial also may impair our business operations. If any of the risks described below were to occur, our business, financial condition, operating results, and cash flows could be materially adversely affected. In such an event, the trading price of our common stock could decline, and you could lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Prospectus, including our consolidated financial statements and related notes. The risks discussed below include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements.

 

Risks Related to Financial Condition

 

We are a development-stage therapeutic organization whose primary focus in the foreseeable future will be the clinical progression of Sigyn Therapy toward market clearance.

 

We are a development stage company with no approved medical products. To date, we have devoted substantially all of our resources to support the development of Sigyn Therapy. This includes the completion in vitro blood purification validation studies, animal studies, the establishment of initial manufacturing protocols, staffing our organization, establishing our intellectual property portfolio, drafting regulatory documents and raising capital to support these activities. However, there is no assurance that we will obtain the capital resources necessary to continue to advance Sigyn Therapy or other product candidates toward market approval.

 

We have incurred significant net losses since inception and do not anticipate that we will generate revenue in the near future. It is expected that we will continue to incur substantial net losses in the foreseeable future and we may never achieve profitability.

 

We are a development-stage medical technology company. Investment in development-stage therapeutic organizations is speculative based on the need for substantial capital resources and the risk that therapeutic candidates will not receive regulatory approval or become commercially viable if market cleared. We have incurred losses in each year since inception. Our net losses were approximately $3.0 million and $1.3 million for the years ended December 31, 2021 and 2020, respectively, and our net losses for the nine months ended September 30, 2022 were approximately $1.6 million. As of December 31, 2021 and September 30, 2022, we had an accumulated deficit of approximately $4.3 million and $6.3 million respectively. We expect to continue to spend significant resources to fund the clinical progression of Sigyn Therapy and other potential product candidates.

 

Going Concern Risk Factor.

 

As described in our audited financial statements for the year ended December 31, 2021 contained elsewhere in this prospectus for that same time period, our independent registered public accounting firm included an explanatory paragraph indicating that our current liquidity position raises substantial doubt about our ability to continue as a going concern. It is anticipated that we will continue to operate as a going concern until the completion of this offering; however, there are no assurances that we will be able to continue our operations if this offering is delayed.

 

Upon the completion of this offering, we may require additional capital in the future to fund the continuance of our operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate our clinical development programs.

 

We believe that the net proceeds from this offering will be approximately $____ million, based on an assumed public offering price of $[__] per Class A Unit and Class B Unit, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We believe that such proceeds will fund our operations plan for up to 24 months after the completion of the offering. Accordingly, we acknowledge that there will be a need to raise additional capital to fund future operations, which may include the continued clinical progression of Sigyn Therapy and other potential product candidates. However, our business or operations plan may change as a result of factors currently unknown to us, and we may need to seek additional funds sooner than planned. However, there is no assurance that we will be able to secure funding when we need it or on favorable terms. Additionally, our ability to raise additional capital could be adversely impacted by market conditions or a worsening global economic climate.

 

6
 

 

Purchasers of our stock will experience dilution.

 

At September 30, 2022 and December 31, 2021, we had a net tangible book value of approximately $0.004 and $0.012 per share of our common stock, respectively. If you purchase our common stock from us in our Offering, you will experience immediate and substantial dilution to the extent of the difference between the public offering price per share of our common stock (assuming a $          per share public offering price, which is the assumed public offering price set forth on the cover page of this prospectus) and the as adjusted net tangible book value per share of our common stock immediately after the offering of $       per share (assuming all          shares in the Offering are sold at $        per share, which is the assumed public offering price set forth on the cover page of this prospectus).

 

A small group of Company officers and directors hold a majority of the control of the Company.

 

As of December 22, 2022, the Company’s executive officers and directors beneficially owned approximately 68.9% of the Company’s outstanding common stock. By virtue of such stock ownership, the principal shareholders are able to control the election of the members of the Company’s Board of Directors and to generally exercise control over the affairs of the Company. Such concentration of ownership could also have the effect of delaying, deterring or preventing a change in control of the Company that might otherwise be beneficial to stockholders. There can be no assurance that conflicts of interest will not arise with respect to such directors or that such conflicts will be resolved in a manner favorable to the Company.

 

Intellectual Property Risk Factors

 

We currently own the rights to U.S. and foreign patents pending and patent applications and endeavor to continually improve our intellectual property position. We consider the protection of our technology to be vital to our business. While we intend to focus primarily on patentable technology, we may also rely on trade secrets, unpatented property, know-how, regulatory exclusivity, patent extensions and continuing technological innovation to develop our competitive position. We also own rights to the trademarks Sigyn Therapeutics™ and Sigyn Therapy™.

 

Our success will depend in large part on our ability to protect our proprietary technologies, including Sigyn Therapy, and to operate without infringing the proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality agreements, and other agreements to establish and protect our proprietary rights. Our success also depends, in part, on our ability to avoid infringing patents issued to others. If we were judicially determined to be infringing on any third-party patent, we could be required to pay damages, alter our products or processes, obtain licenses, or cease sales of products or certain activities.

 

It is possible that our pending patent applications may not result in issued patents, and that we will not develop additional proprietary products that are patentable, that any patents issued to us may not provide us with competitive advantages or will be challenged by third parties and that the patents of others may prevent the commercialization of products incorporating our technology. Furthermore, others may independently develop similar products, duplicate our products or design around our patents. U.S. patent applications are not immediately made public, so it is possible that a third party may obtain a patent on a technology we are actively using. Additionally, there is a risk that any patent applications that we file or later obtain could be challenged by third parties and declared invalid or unenforceable.

 

Patent law outside the United States is uncertain and currently undergoing review and revisions in many countries. The laws of some countries may not protect our proprietary rights to the same extent as the laws of the United States. Third parties may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that may be issued or pending in the United States. In addition to patent protection, we rely on unpatented trade secrets and proprietary technological expertise. It is possible that others could independently develop or otherwise acquire substantially equivalent technology or somehow gain access to our trade secrets and proprietary technological expertise.

 

We Face Industry & Competition Risks

 

Based on the size of the market opportunity, the industry to treat sepsis and other life-threatening inflammatory conditions is expected to become extremely competitive. As a development-stage device, Sigyn Therapy faces the challenge of establishing medical industry support, which will be driven by treatment data resulting from human clinical studies. Should Sigyn Therapy become market cleared, we are likely to face significant competition. Additionally, we will need to establish large-scale production of Sigyn Therapy in order to be competitive in the marketplace.

 

7
 

 

In the absence of approved drug agents to treat sepsis and other life-threatening disorders, our competition is likely to come from organizations that develop extracorporeal blood purification therapies. Among these therapies are a cytokine adsorption technology (CytoSorb from Cytosorbents Corporation); a technology that removes circulating endotoxin (Toraymyxn from Toray Industries); and two devices that target the removal of pathogens from the bloodstream (the Hemopurifier from Aethlon Medical) and (the Seraph-100 Microbind Affinity Filter from Exthera Medical).

 

CytoSorb is a clinical-stage therapeutic candidate in the United States and market cleared in more than 40 countries outside the U.S. CytoSorb was recently cleared to treat severe COVID-19 infections under FDA Emergency-Use Authorization (EUA) based on its ability to adsorb inflammatory cytokines from the bloodstream.

 

Toraymyxn is a clinical-stage therapeutic candidate in the United States and broadly market cleared outside the U.S. Toraymyxn houses an immobilized antibiotic agent with a high specificity to bind circulating endotoxin, a potent activator of sepsis resulting from gram-negative bacterial infections. In North America, exclusive rights to Toraymyxin are licensed to Spectral Medical, who is conducting FDA approved studies to treat sepsis.

 

The Aethlon Hemopurifier is a clinical-stage therapeutic candidate in the United States. The Hemopurifier has been cleared to treat severe COVID-19 infections through an FDA IDE supplement and was previously cleared under FDA Emergency-Use Authorization (EUA) to treat Ebola virus. Immobilized within the Hemopurifier is an affinity lectin that has a high specificity to bind a broad-spectrum of viral pathogens from the bloodstream.

 

The Exthera Seraph-100 Microbind Affinity Filter is a clinical-stage therapeutic candidate in the United States and market cleared outside the U.S. for the removal of bloodstream pathogens. The Seraph-100 was recently cleared and broadly deployed to treat severe COVID-19 infections under FDA Emergency-Use Authorization (EUA). The Seraph-100 incorporates heparin-coated polyethylene beads that bind both viral and bacterial pathogens in the bloodstream.

 

While preclinical in vitro studies have quantified the reduction of viral pathogens, bacterial toxins and inflammatory mediators from human blood plasma with small-scale versions of Sigyn Therapy, there is no assurance that we will receive market clearance for our product or be able to establish scalable manufacturing that would allow us to compete with these and other emerging therapies.

 

Government Regulation May Cause Us Delays in Ability to Obtain Approval

 

Sigyn Therapy is subject to regulation by numerous regulatory bodies, including the United States Food and Drug Administration (FDA) and comparable international regulatory agencies. These agencies will require that we comply with applicable laws and regulations governing the development, testing, manufacturing, labeling, marketing, storage, distribution, advertising and promotion, and post-marketing surveillance of Sigyn Therapy. As a medical device, the FDA’s Center for Devices and Radiological Health (CDRH) will have primary jurisdiction over the premarket development, review, and approval of Sigyn Therapy. Failure to comply with applicable requirements could subject us to a variety of administrative sanctions, such as issuance of warning letters, import detentions, civil monetary penalties and/or judicial sanctions, such as product seizures, injunctions, and criminal prosecution.

 

FDA’s Pre-market Approval (PMA) Pathway May Take a Long Time for Approval of our Product

 

The FDA is likely to classify our lead product candidate, Sigyn Therapy, as a significant risk Class III device, which would require extensive pre-clinical and clinical studies to be conducted along with the submission of a Pre-Market Approval (PMA) application prior to market clearance consideration by FDA. The commercialization of medical devices in the United States requires either a prior 510(k) clearance, unless it is exempt, or a PMA from the FDA. Medical devices are classified into one of three classes; Class I, Class II or Class III which are determined by the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. A Class III device cannot be marketed in the United States unless the FDA approves the device after submission of a PMA. We believe that Sigyn Therapy will be classified as a Class III device and as such will be subject to a PMA submission and approval.

 

A pre-market approval application must be supported by extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and labelling to demonstrate to the FDA’s satisfaction reasonable evidence of safety and effectiveness of the device.

 

After a pre-market approval application is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive review and thus whether the FDA will file the application for review. The FDA has 180 days to review a filed pre-market approval application, although the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device.

 

8
 

 

Although the FDA is not bound by the advisory panel decision, the panel’s recommendations are important to the FDA’s overall decision-making process. In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation, or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA’s regulations.

 

Upon completion of the PMA review, the FDA may: (i) approve the PMA which authorizes commercial marketing with specific prescribing information for one or more indications, which can be more limited than those originally sought; (ii) issue an approvable letter which indicates the FDA’s belief that the PMA is approvable and states what additional information the FDA requires, or the post-approval commitments that must be agreed to prior to approval; (iii) issue a not approvable letter which outlines steps required for approval, but which are typically more onerous than those in an approvable letter, and may require additional clinical trials that are often expensive and time consuming and can delay approval for months or even years; or (iv) deny the application. If the FDA issues an approvable or not approvable letter, the applicant has 180 days to respond, after which the FDA’s review clock is reset.

  

The advancement of Sigyn Therapy will be reliant on substantial funding, of which there is no assurance that we will raise the capital resources necessary to maintain the continuance of our operations and clinically advance Sigyn Therapy. Even if we obtain market clearance from FDA to commercialize Sigyn Therapy, there is no assurance that we can successfully compete with other products in the marketplace. Additionally, competitive technologies could emerge that are more effective in treating life-threatening indications targeted by Sigyn Therapy. Such competitive products may be advanced by larger organizations that have substantially greater capital resources and marketing capabilities. Furthermore, Sigyn Therapy may be deemed obsolete should emerging competitive technologies be commercialized prior to market clearance of Sigyn Therapy. Since inception, our primary focus has been directed toward the advancement of Sigyn Therapy. As of September 30, 2022, we have an accumulated deficit of $6.3 million and a working capital deficit of $1.6 million.

 

Clinical Trial Requirements Pose Risk to Obtaining Approval

 

Human clinical trials are required to support pre-market approval. In the United States, human clinal studies require the submission of an Investigational Device Exemption (IDE) to FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol is scientifically sound. At present, we are preparing an IDE to submit to FDA. Prior to initiating human studies, our IDE will need to be approved in advance by the FDA for a specific number of patients at specified study sites. During the trial, we must comply with the FDA’s IDE requirements for investigator selection, trial monitoring, reporting and recordkeeping. Our clinical trial investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of investigational devices and comply with all reporting and recordkeeping requirements. Clinical trials of Sigyn Therapy will not be allowed to begin until our IDE application has been approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical trial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involving subjects and which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety and welfare of human research subjects. The FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and effectiveness of Sigyn Therapy or other product candidates.

 

The success of Sigyn Therapy and other product candidates will depend on several factors, which include:

 

● the completion of clinical studies that demonstrate the safety and efficacy of our products; the receipt of market approval from applicable regulatory authorities, and the completion of post-market studies that may be required by applicable regulatory authorities;

 

the establishment of commercial manufacturing capabilities and launch of product marketing and commercial sales;

 

● the acceptance of Sigyn Therapy or other product candidates by patients, the medical community and third-party payors;

 

obtaining and maintaining healthcare coverage and adequate reimbursement for Sigyn Therapy and other product candidates.

 

Many of these factors may be beyond our control, including the time that will be required to complete clinical testing, the regulatory submission process, and a change in the competitive landscape. It is possible that none of our product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete clinical trials, obtain regulatory approval or, if approved, commercialize our product candidates, which would materially harm our business, financial condition and the results of our operations.

 

9
 

 

Our Pre-clinical Outcomes May Not Be Predictive of Clinical Trial Success

 

The results of our pre-clinical in vitro validations and animal studies may not be predictive of human clinical study outcomes. Historically, therapeutic candidates that perform satisfactorily in pre-clinical and animal studies may nonetheless fail to obtain marketing approval. If the results of our clinical studies are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may:

 

be delayed in obtaining marketing approval for our product candidates, if approved at all;

 

obtain approval for indications or patient populations that are not as broad as intended or desired;

 

be required to change the way our product is administered;

 

●be required to perform additional clinical studies to support approval or be subject to additional post-marketing testing requirements;

 

● have regulatory authorities withdraw their approval of a product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy.

 

Additionally, our product candidates could potentially cause adverse events that have not yet been predicted. The inclusion of ill patients in our clinical studies may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As described above, any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products.

 

We will depend on enrollment and retention of patients in our clinical trials for our product candidates. Delays or difficulties enrolling or retaining patients in our clinical trials could adversely impact our business operations.

 

The successful and timely completion of clinical trials will require that we enroll and retain a sufficient number of patient candidates. Any clinical trials that we conduct could be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal, or adverse events. These types of developments could cause us to delay a clinical trial or halt further development. Patient enrollment depends on many factors, including:

 

the size and nature of the patient population;

 

the severity of the disease, condition or infection under investigation;

 

● eligibility criteria for the trial;

 

the proximity of patients to clinical sites;

 

● the design of the clinical protocol;

 

● the ability to obtain and maintain patient consents;

 

perceived risks and benefits of the product candidate under evaluation;

 

the ability to recruit clinical trial investigators with the appropriate competencies and experience;

 

● the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion;

 

the availability of competing clinical trials;

 

● the availability of candidate patients during pandemic outbreaks, such as COVID-19; and

 

the availability of new therapies that are approved for the indication the clinical trial is investigating.

 

These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of our clinical trials may jeopardize our ability to commence product sales and generate revenue. Additionally, factors that delay the commencement or completion of clinical trials may establish a basis for FDA to deny the approval of our therapeutic candidates.

 

10
 

 

Risks Related to our Business and Industry

 

We are dependent on our Chief Executive Officer.

 

We are dependent on our Chief Executive Officer, James A. Joyce, who is integral to our business operations and the development of our product candidates. The loss of Mr. Joyce’s services could have a material adverse effect on our business operations.

 

We have a limited number of employees.

 

We are a small organization that maintains a staff of five employees. The departure of any employee could have a material adverse effect on our business operations.

 

We may be adversely affected by current and future pandemic outbreaks.

 

The current COVID-19 (“COVID-19”) outbreak and the emergence of future pandemics could have a deleterious impact on our business operations. As demonstrated by COVID-19, pandemic outbreaks can significantly delay or interrupt crucial business operations. Pandemic outbreaks may also reduce the availability of human resources or critical supplies that will be required to carry out our clinical and manufacturing programs. Additionally, stay-at-home and other pandemic outbreak policies could restrict critical personnel from conducting the core activities necessary to advance Sigyn Therapy and other potential product candidates.

 

Economic uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled.

 

Generally, worldwide economic conditions remain uncertain. Access to capital markets is critical to our ability to operate. Traditionally, medical technology companies have funded their research and development expenditures through raising capital in the equity markets. Declines and uncertainties in these markets in the past have severely restricted raising new capital and have affected companies’ ability to continue to expand or fund clinical development efforts. There is no certainty that the capital markets will be conducive to raising capital on favorable terms. If economic conditions become worse, our future cost of equity or debt capital and access to the capital markets could be adversely affected. In addition, if we are unable to access the capital markets on favorable terms, our ability to execute our clinical progression plan would be compromised. Moreover, we rely and intend to rely on third-party vendors, including clinical research organizations, contract manufacturing organizations and consultants. Global economic conditions may result in a disruption or delay in the performance of our third-party contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected.

 

Our reliance on third-party vendors heightens the risks faced by our business.

 

We rely on third-party vendors for certain key aspects of our business, including support for information technology systems and certain human resource functions. We do not control these partners, but we depend on them in ways that may be significant to us. If these parties fail to meet our expectations or fulfill their obligations to us, we may fail to receive the expected benefits. In addition, if any of these third parties fails to comply with applicable laws and regulations in the course of its performance of services for us, there is a risk that we may be held responsible for such violations as well, which could adversely affect our business, reputation, financial condition or results of operations.

 

We rely on third party organizations to conduct our pre-clinical testing, research and clinical trials.

 

We rely on third-party organizations to conduct preclinical studies, and we expect to continue to rely on third parties, such as contract research organizations (“CROs”), contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and pre-clinical testing. These third parties may terminate their engagements with us at any time. If these third parties do not successfully carry out their duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we are required to enter into alternative arrangements, it could delay our product development activities.

 

11
 

 

Upon commercialization of our products, we may be dependent on third parties to market, distribute and sell our products.

 

Our ability to generate revenues may be dependent upon the sales and marketing efforts of any future co-marketing partners and third-party distributors. At this time, we have not entered into an agreement with any commercialization partner and only plan to do so prior to commercialization. If we fail to reach an agreement with any commercialization partner, or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business, financial condition and results of operations.

 

We will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.

 

We do not have any manufacturing facilities. We expect to rely on third-party manufacturers for the manufacture of our product candidates for clinical trials and for commercial supply of any product candidate for which we obtain marketing approval.

 

We may be unable to establish agreements with third-party manufacturers for clinical or commercial supply on terms favorable to us, or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 

reliance on the third party for regulatory compliance and quality assurance;
   
the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and
   
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

 

Third-party manufacturers may not be able to comply with U.S. Current Good Manufacturing Practices (cGMPs) or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.

 

Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.

 

Any performance failure on the part of our manufacturers, including a failure that may not relate specifically to our product candidates or approved products, could delay clinical development or marketing approval or adversely impact our ability to generate commercial sales. If our contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer.

 

Our anticipated future dependence upon others for the manufacture of our current and future product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.

 

Our business could be adversely affected by reliance on sole suppliers.

 

Notwithstanding our current multiple supplier approach, certain essential product components may be supplied in the future by sole, or a limited group of, suppliers. Most of our products and components are purchased through purchase orders rather than through long term supply agreements and large volumes of inventory may not be maintained. There may be shortages and delays in obtaining certain product components. Disruption of the supply or inventory of components could result in a significant increase in the costs of these components or could result in an inability to meet the demand for our products. In addition, if a change in the manufacturer of a key component is required, qualification of a new supplier may result in delays and additional expenses in meeting customer demand for products. These factors could adversely affect our revenues and ability to retain our experienced sales force.

 

12
 

 

Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported results of operations.

 

We are required to prepare our financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which is periodically revised and/or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies, including the FASB and the SEC. It is possible that future accounting standards we are required to adopt may require additional changes to the current accounting treatment that we apply to our financial statements and may require us to make significant changes to our reporting systems. Such changes could result in a material adverse impact on our business, results of operations and financial condition.

 

We have a limited operating history, which may make it difficult to evaluate our business and prospects.

 

We face the risks associated with businesses in their early stages, with limited operating histories and whose prospects are hard to evaluate. Any evaluation of our business and our prospects must be considered in light of the uncertainties, delays, difficulties and expenses commonly experienced by companies at this stage, which generally include unanticipated problems and additional costs relating to the development and testing of products, product approval or clearance, regulatory compliance, production, product introduction and marketing, and competition. Many of these factors are beyond the control of our management. In addition, our performance will be subject to other factors beyond our control, including general economic conditions and conditions in the healthcare industry.

 

Market acceptance of Sigyn Therapy and other product candidates will be vital to our future success.

 

The commercial success of our products is dependent upon their acceptance by the intended markets. Our product candidates may not gain or maintain any significant degree of market acceptance among consumers, surgeons or healthcare providers, or acceptance by third-party payors, such as health insurance companies, Medicaid and Medicare. We cannot be certain that our products will be used by the medical community, even upon market approval of our product candidates.

 

Market acceptance will be dependent on numerous factors, many of which are not under our control, including:

 

  the safety and efficacy of our products and product candidates, as demonstrated in clinical trials and after commercialization;
  favorable regulatory approval and product labeling;
  the ease of use of our product and any related instrumentation that accompany our product;
  our ability to educate and train doctors on the advantages of our product;
  the price of any approved product relative to alternative technologies; and
  the availability of third-party reimbursement.

 

If our products and product candidates do not achieve significant market acceptance, our potential for revenues and profitability would be adversely affected.

 

13
 

 

Our employees, independent contractors, principal investigators, consultants, vendors and clinical research organizations, or CROs, could engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

 

We are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors and CROs may engage in fraudulent or other illegal activity. Misconduct by these persons could include intentional, reckless or negligent conduct or unauthorized activity that violates laws or regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions or other actions stemming from a failure to comply with such laws or regulations, and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in connection with government contracts and require certain contractors to maintain a code of business ethics and conduct. If any such actions are instituted against us, we may have to terminate employees or others involved and the impact of such termination can result in our experiencing delays and additional costs associated with replacing the services being provided. If we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our operating results.

 

U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of future product candidates and to manufacture, market and distribute our products after approval is obtained.

 

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

 

Information Technology Risks

 

Our internal information technology (IT) systems could be compromised, damaged, breached or destroyed. IT risks include hardware and software failure, human error, spam, viruses, malicious attacks, industrial espionage, as well as natural disasters such as fires, earthquakes, hurricanes or floods. IT system failures may affect our ability to run our operations. Operational impact of IT failures or breaches may result in loss of productivity and a reduced ability to advance our clinical programs. Failures or breaches of our IT systems could also result in the loss or corruption of confidential data or in the theft of data or critical information.

 

Additionally, the increased sophistication and activities of perpetrators of cyber-attacks have resulted in an increase in information security risks in recent years. Hackers develop and deploy viruses, worms, and other malicious software programs that attack products and services and gain access to networks and data centers. If we experience difficulties maintaining existing systems or implementing new systems, we could incur significant losses due to disruptions in our operations. Additionally, these systems may contain valuable proprietary and confidential information and may contain personal data of employees, third-party vendors, and collaborators. A security breach could result in disruptions of our internal systems and business applications, harm to our competitive position from the compromise of confidential business information, or subject us to liability under laws that protect personal data. As cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities. Any of these consequences could adversely affect business.

 

Risk Factors Related to Our Common Stock

 

The price of our common stock may be volatile, and a shareholder’s investment in our common stock could suffer a decline in value.

 

There has been significant volatility in the volume and market price of our common stock, and such volatility may continue in the future. In addition, factors such as quarterly variations in our operating results, actions by governmental agencies, national economic and stock market considerations as well as other events and circumstances beyond our control, including the effects of pandemic outbreaks, could have a significant impact on the future market price of our common stock and the relative volatility of such market price.

 

A prolonged decline in the price of our common stock could result in a reduction in the liquidity of our common stock and a reduction in our ability to raise capital. If we are unable to raise the funds required for all of our planned operations and key initiatives, we may be forced to allocate funds from other planned uses, which may negatively impact our business and operations, including our ability to develop new products and continue our current operations.

 

14
 

 

Our common stock is currently traded on the OTCQB® Venture Market, which may have an unfavorable impact on our stock price and liquidity.

 

While we plan to submit an application to list our common stock on the Nasdaq Capital Market, our stock currently trades on the OTCQB® Venture Market. The OTCQB® Venture Market is significantly more limited market than the national securities exchanges such as the New York Stock Exchange, or Nasdaq stock exchange, and there are lower financial or qualitative standards that a company must meet to have its stock traded on the OTCQB® Venture Market. OTCQB® Venture Market is an inter-dealer quotation system much less regulated than the major exchanges, and trading in our common stock may be subject to abuses, volatility and shorting, which may have little to do with our operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated to operating performance. The Financial Industry Regulatory Authority (“FINRA”) has adopted rules that require a broker-dealer to have reasonable grounds for believing an investment is suitable for that customer when recommending an investment to a customer. FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for some customers and may make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may result in a limited ability to buy and sell our stock. Consummation of this offering is contingent upon our common stock being accepted for listing on Nasdaq.

 

Our common shares are currently subject to the “Penny Stock” rules of the SEC, and the trading market in our securities will likely be limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

 

The Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require:

 

  That a broker or dealer approve a person’s account for transactions in penny stocks; and
  The broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quality of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:

 

  Obtain financial information and investment experience objectives of the person; and
  Make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form:

 

  Sets forth the basis on which the broker or dealer made the suitability determination; and
  That the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commission’s payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

We do not intend to pay any cash dividends on our shares of common stock in the near future, so our shareholders will not be able to receive a return on their shares unless they sell their shares.

 

We do not anticipate paying any cash dividends on our common stock in the foreseeable future. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend. Unless we pay dividends, our shareholders will not be able to receive a return on their shares unless they sell such shares.

 

15
 

 

Raising additional capital may cause dilution to our existing stockholders and investors in this offering, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.

 

We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or through the issuance of shares under other types of contracts, or upon the exercise or conversion of outstanding options, warrants, convertible debt or other similar securities, the ownership interests of our stockholders will be diluted, and the terms of such financings may include liquidation or other preferences, antidilution rights, conversion and exercise price adjustments and other provisions that adversely affect the rights of our stockholders, including rights, preferences and privileges that are senior to those of our holders of common stock in terms of the payment of dividends or in the event of a liquidation. In addition, debt financing, if available, could include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends and may require us to grant security interests in our assets. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, product or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may need to curtail or cease our operations.

 

There is no established market for the Series B Preferred Stock or Series A Warrants being offered in this offering.

 

There is no established trading market for the Series B Preferred Stock or Series A Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Series B Preferred Stock or Series A Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Series B Preferred Stock or Warrants will be limited.

 

Holders of Series B Preferred Stock will have limited voting rights.

 

Except with respect to certain material changes in the terms of the Series B Preferred Stock and certain other matters and except as may be required by Delaware law, holders of Series B Preferred Stock will have no voting rights. Holders of Series B Preferred Stock will have no right to vote for any members of our board of directors.

 

The Series A Warrants are speculative.

 

The Series A Warrants offered in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of our common stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the Series A Warrants may exercise their right to acquire the common stock and pay an exercise price of $____ per share (110% of the public offering price of our Class A Units in this offering), prior to five years from the date of issuance, after which date any unexercised warrants will expire and have no further value. Moreover, following this offering, the market value of the Series A Warrants is uncertain and there can be no assurance that the market value of the Series A Warrants will equal or exceed their public offering price. There can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the Series A Warrants, and consequently, whether it will ever be profitable for holders of the warrants to exercise the Series A Warrants.

 

The Series A Warrants may not have any value and if an active, liquid trading market for the Series A Warrants does not develop, you may not be able to sell your warrants quickly or at or above the price you paid for them.

 

The Series A Warrants issued in this offering will be immediately exercisable and expire five years after their issuance. The Series A Warrants will have an initial exercise price equal to $            . In the event that our common stock price does not exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants may not have any value.

 

Prior to this offering, there has been no public market for any of our warrants and we do not intend to list the Series A Warrants on the Nasdaq Capital Market or any other exchange. As a result, an active trading market may not develop for the Series A Warrants to be sold in this offering or, if developed, may not be sustained, and the market for the Series A Warrants may be volatile or may decline regardless of our operating performance. The lack of an active market may impair your ability to sell your Series A Warrants at the time you wish to sell them or at a price that you consider reasonable.

 

The exercise price of the Series A Warrants offered by this prospectus will not be adjusted for certain dilutive events.

 

The exercise price of the Series A Warrants offered by this prospectus are subject to adjustment for certain events, including, but not limited to, the payment of a stock dividend, stock splits, certain issuances of capital stock, options, convertible securities and other securities. However, the exercise prices will not be adjusted for dilutive issuances of securities and there may be transactions or occurrences that may adversely affect the market price of our common stock or the market value of such warrants without resulting in an adjustment of the exercise prices of such warrants.

 

There is no assurance that we will fulfill or maintain the listing requirements of the NASDAQ.

 

We are applying to list our common stock on the Nasdaq Capital Market, a national securities exchange. An approval of our listing application by NASDAQ will be subject to, among other things, our ability to fulfill all of the listing requirements of NASDAQ. There is no assurance that our securities will become NASDAQ listed and even if our shares become NASDAQ listed, there is no assurance that an active trading market for our securities will develop or be sustained. If our common stock is not accepted for listing on NASDAQ, we will not proceed with the consummation of this offering.

 

In addition, NASDAQ has rules for continued listing, including, without limitation, minimum market capitalization and other requirements. Failure to maintain our listing, or de-listing from NASDAQ, would make it more difficult for shareholders to dispose of our securities and more difficult to obtain accurate price quotations on our securities. This could have an adverse effect on the price of our common shares. Our ability to issue additional securities for financing or other purposes, or otherwise to arrange for any financing we may need in the future, may also be materially and adversely affected if our common shares and/or other securities are not traded on a national securities exchange.

 

16
 

 

If we are unable to meet the NASDAQ listing criteria, our common shares may continue to trade on the OTC Pink Sheets.

 

We are applying for our common stock to be listed on NASDAQ, a national securities exchange. The NASDAQ requires companies desiring to list their common stock to meet certain listing criteria including total number of shareholders: minimum stock price (which will necessitate that we effect a reverse split of our issued and outstanding common stock before listing), total value of public float, and in some cases total shareholders’ equity and market capitalization. Our failure to meet such applicable listing criteria could prevent us from listing our common stock on NASDAQ, and if we do not list on NASDAQ, we will not proceed with this offering. In the event we are unable to have our shares traded on NASDAQ, our common stock may continue to trade on the OTC Pink Sheets, which is less liquid and more volatile than the NASDAQ. Our failure to have our shares traded on NASDAQ could make it more difficult for you to trade our shares, could prevent our common stock trading on a frequent and liquid basis and could result in the value of our common stock being less than it would be if we were able to list our shares on NASDAQ.

 

Our Amended and Restated Certificate of Incorporation provides that the Court of Chancery in the State of Delaware is the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

 

Our Amended and Restated Certificate of Incorporation, or our Certificate of Incorporation, provides that, unless our Board of Directors consents to an alternative forum, the Court of Chancery in the State of Delaware will be the sole and exclusive forum for: (i) any derivative action or proceeding brought by or on our behalf; (ii) any direct action asserting a claim against us or any of our directors or officers pursuant to any of the provisions of the General Corporation Law of the State of Delaware, or our Certificate of Incorporation; (iii) any action asserting a claim of breach of fiduciary duties owed by any of our directors, officers or other employees to our stockholders; or (iv) any action asserting a violation of Delaware decisional law relating to our internal affairs. This provision does not apply to (a) actions in which the Court of Chancery in the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of Delaware courts, or (b) actions in which a federal court has assumed exclusive jurisdiction to a proceeding. This choice of forum provision is not intended to apply to any actions brought under the Securities Act of 1933, as amended, or the Securities Act, or the Securities Exchange Act of 1934, as amended, or the Exchange Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.  There is uncertainty as to whether a court would enforce this provision with respect to claims under the Securities Act. However, our Certificate of Incorporation does not relieve us of our duties to comply with federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations. Our Certificate of Incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and consented to this choice of forum provision.

 

This choice of forum provision may impose additional litigation costs on stockholders in pursuing such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, this choice of forum provision may limit our stockholders’ ability to bring a claim in a judicial forum that they find favorable for disputes, which may discourage the filing of such lawsuits.

 

We will have broad discretion in the use of the net proceeds to us from this offering and may not use them effectively.

 

We will have broad discretion in the application of the net proceeds to us from this offering, including for any of the purposes described in the section titled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, our ultimate use may vary substantially from our currently intended use. Investors will need to rely upon the judgment of our management with respect to the use of proceeds. Pending use, we may invest the net proceeds from this offering in investment-grade, interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government that may not generate a high yield for our stockholders. If we do not use the net proceeds that we receive in this offering effectively, our business, financial condition, results of operations and prospects could be harmed, and the market price of our common stock could decline.

 

17
 

 

We are an “emerging growth company,” and we cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

 

We are an “emerging-growth company,” as defined in the JOBS Act, and we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section 107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements will not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards.

 

We will remain an emerging-growth company until the earliest of: (1) the last day of the fiscal year following the fifth anniversary of this offering; (2) the last day of the first fiscal year in which our annual gross revenue is $1.235 billion or more; (3) the date on which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities; and (4) the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates.

 

We cannot predict if investors will find our common stock less attractive as a result of choosing to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations will not be as comparable to the results of operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.

 

18
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

 

These forward-looking statements include, but are not limited to, statements about:

 

our use of net proceeds from this offering;
   
the continued development and growth of the demand and markets for our products;
   
our ability to raise future capital through debt or equity financing transactions;
   
our ability to attract and retain key employees;
   
our ability to manage growth in our business; and
   
our ability to identify and successfully execute strategic partnerships.

 

Although we base the forward-looking statements contained in this prospectus on assumptions that we believe are reasonable, we caution you that actual results and developments (including our results of operations, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this prospectus. In addition, even if results and developments are consistent with the forward-looking statements contained in this prospectus, those results and developments may not be indicative of results or developments in subsequent periods. Certain assumptions made in preparing the forward-looking statements contained in this prospectus include:

 

our ability to implement our business strategies;
   
our ability to complete the development of products on time and on budget;
   
our competitive advantages;
   
our ability to obtain and maintain financing on acceptable terms;
   
the impact of competition;
   
the changes and trends in the life sciences industry;
   
changes in laws, rules and regulations;
   
our ability to maintain good business relationships with our exclusive independent operators and strategic partners;
   
our ability to keep pace with changing consumer preferences;
   
our ability to protect our intellectual property;
   
our ability to identify, manage and integrate acquisitions;
   
our ability to retain key personnel; and
   
the absence of material adverse changes in our industry or the global economy, including as a result of the COVID-19 pandemic.

 

19
 

 

These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this prospectus. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC, after the date of this prospectus. See “Where You Can Find More Information”.

 

This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

 

In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors”. These and other factors could cause our future performance to differ materially from our assumptions and estimates.

 

20
 

 

USE OF PROCEEDS

 

We estimate that the net proceeds from the sale of _____Class A Units (assuming no purchase of Class B Units) will be approximately $____ million, or approximately $____ million if the underwriter exercises in full its option to purchase additional shares of our common stock and/or Series A Warrants, based on an assumed public offering price of $ per Class A Unit, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed public offering price of $____ per Class A Units would increase (decrease) the net proceeds to us from this offering by approximately $___ million, or approximately $___ million if the underwriter exercises its over-allotment option in full, assuming the number of Class A Units offered by us, as set forth on the cover page of this prospectus, remain the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

The expected use of net proceeds of this offering represents our current intentions based upon our present plan and business conditions. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors. As a result, management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering. We currently estimate that we will use the net proceeds from this offering as follows: ______________________ We have presumed that we will receive aggregate gross proceeds of $____ million and deducted $___ million payable in offering costs, commissions and fees.

 

We intend to use the net proceeds from this offering as follows:

 

Approximately 34% to fund research and the continued development of Sigyn Therapy; and
   

Approximately 66% for working capital and other general corporate purposes, including the additional costs with being a public company.

 

Based on our current business plans, we believe that the net proceeds of this offering, together with our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for approximately the next two years from the date of this prospectus.

 

We believe the net proceeds will enable us to complete the first-in-human feasibility study of Sigyn Therapy in End-Stage Renal Disease patients suffering from excel inflammation and/or endotoxemia in additional to pursing additional product advancements. In addition, we will begin development and testing of ChemoPrepTM and ChemoPure TM with a primary objective to enhance tumor site delivery of chemotherapy and reduce its toxicity and secondary objective to reduce treatment dosing without sacrificing patient benefit. The company does not intend to discharge any indebtedness with the proceeds of the transaction.

 

This expected use of proceeds from this offering represents our intentions based upon current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above.

 

The amount and timing of our actual expenditures will depend on numerous factors, including the results of our research and development, the anticipated growth out our business and any unforeseen cash needs. As a result, our management will have broad discretion over the use of proceeds from this offering.

 

The use of the proceeds represents management’s estimates based upon current business and economic conditions. We reserve the right to use of the net proceeds we receive in the offering in any manner we consider to be appropriate. Although our Company does not contemplate changes in the proposed use of proceeds, to the extent we find that adjustment is required for other uses by reason of existing business conditions, the use of proceeds may be adjusted. The actual use of the proceeds of this offering could differ materially from those outlined above as a result of several factors including those set forth under “Risk Factors” and elsewhere in this prospectus.

 

21
 

 

DETERMINATION OF OFFERING PRICE

 

The offering price of the Class A Units and Class B Units will be negotiated between the underwriters and us considering our historical performance and capital structure, prevailing market conditions, and overall assessment of our business. Our common stock currently trades on the OTCQB® Venture Market under the symbol “SIGY.” On November 4, 2022, the last reported sale price of our common stock was $0.26 per share.

 

MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS

 

Our common stock currently trades on the OTCQB® Venture Market.

 

As of December 22, 2022, we had approximately 306 shareholders of record of our shares of common stock.

 

We intend to apply to list our common stock on the Nasdaq Capital Market under the symbol “SIGY.” No assurance can be given that such application will be approved or that a trading market will develop. If, for whatever reason, Nasdaq does not confirm the listing of our common stock on Nasdaq prior to the pricing of the offering, we will not be able to consummate and will terminate this offering.

 

DIVIDEND POLICY

 

We have never paid any cash dividends on our common shares. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future following this offering. Any future determination to pay dividends will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirements and other factors that our Board of Directors deems relevant. In addition, the terms of any future debt or credit financings may preclude us from paying dividends.

 

22
 

 

CAPITALIZATION

 

The following table sets forth our capitalization and cash as of September 30, 2022:

 

  on an actual basis;
     
  on a pro forma basis to reflect the conversion of senior secured debentures; and
     
 

on a pro forma as adjusted basis to reflect the sale by us of ______ Class A Units (assuming no Class B Units are purchased) at the assumed public offering price of $____ per Class A Unit, after deducting the underwriting discounts and commissions and estimated offering costs payable by us; and

 

The pro forma as adjusted information below is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

 

You should read this table together with the section in this prospectus entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included elsewhere in this prospectus. Numbers are expressed in thousands (U.S. dollars) except share and per share data.

 

   As of September 30, 2022 
           Proforma as, 
Capitalization in U.S. Dollars in thousands (except share data)  Actual   Pro Forma   As Adjusted 
Cash  $7   $8,247   $8,254 
Notes payable and senior secured debentures   945    (945)   - 
Common stock, $0.0001 par value per share, 1,000,000,000 shares authorized; 37,295,803 shares issued and outstanding; 44,930,016 shares issued and outstanding pro forma as adjusted  $4   $0.2   $4 
Additional paid in capital   4,423    2,553    6,976 
Accumulated deficit   (5,610)   -    (5,610)
Accumulated other comprehensive income   -    -    - 
Total stockholders’ equity   (1,183)   2,553    1,370 
Total Capitalization  $(238)  $1,608   $1,370 

 

The number of common shares that will be outstanding after this offering set forth above is based on 37,295,803 common shares outstanding as of September 30, 2022.

 

Unless specifically stated otherwise, all information in this prospectus assumes:

 

  assumes no exercise by the underwriters of their option to purchase up to additional shares of our common stock and/or Series A Warrants from us to cover over-allotments, if any;
  assumes no exercise of the representative’s warrants or Series A Warrants to be issued upon consummation of this offering at an exercise price equal to 110% of the initial offering price of the common stock;
  assumes no shares of Series B Preferred Stock are sold in this offering;
  assumes no exercise of outstanding warrants to purchase shares of the Company’s common stock at an exercise price of $[__]; and
  excludes shares of common stock to be reserved for future issuance under our equity incentive plan, which will be effective upon the completion of this offering.

  

To the extent we sell any Class B Units in this offering, the same aggregate number of common stock equivalents resulting from this offering would be convertible under the Series B Preferred Stock issued as part of the Class B Units.

 

(1) A $1.00 increase or decrease in the assumed public offering price per Class A Units would increase or decrease our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total shareholders’ equity and total capitalization by approximately $___ million assuming the number of Class A Units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discount and estimated offering expenses payable by us.

 

23
 

 

DILUTION

 

If you invest in our shares in this offering, your ownership interest will be diluted to the extent of the difference between the initial public offering price per common share of in this offering and the as adjusted net tangible book value per share immediately after this offering. We calculate net tangible book value per share by dividing our net tangible book value, which is tangible assets less total liabilities less debt discounts, by the number of our outstanding common shares as of September 30, 2022. Our historical net tangible book value (deficit) as of September 30, 2022, was approximately $0.015 million or $0.004 per common share.

 

After giving effect to the sale of a _____ Class A Units at an assumed shares at $ per share (and assuming no sale of Class B Units), after deducting the underwriting discounts and commissions and estimated offering costs payable by us, our as adjusted net tangible book value (deficit) as of December 31, 2021, would have been approximately $ million, or per common share. This represents an immediate increase in as adjusted net tangible book value of $ per share to existing shareholders and an immediate dilution of $ per share to investors purchasing our common shares in this offering at the assumed public offering price.

 

The following table illustrates per share dilution as of September 30, 2022:

 

Assumed public offering price per common share      $ - 
Net tangible book value (deficit) per share as of September 30, 2022  $.004      
Increase in net tangible book value (deficit) per share attributable to this offering  $-      
Net tangible book value (deficit) per share after this offering       $- 
Dilution per share to investors participating in this offering       $- 

 

Each $1.00 increase (decrease) in the assumed public offering price per Class A Unit would increase (decrease) our as adjusted net tangible book value (deficit) after this offering by approximately $___ million, or approximately $____ per share, and the dilution per share to new investors by approximately $____ per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remain the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Class A Units we are offering. An increase of 500,000 Class A Units in the number of Class A Units offered by us would increase our as adjusted net tangible book value (deficit) after this offering by approximately $____, or $____ per common share, and decrease the dilution per share to new investors by $____ per common share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a decrease of 500,000 Class A Units offered by us would decrease our as adjusted net tangible book value (deficit) after this offering by approximately $___ million, or $____ per common share, and increase the dilution per share to new investors by $____ per common share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms of this offering determined at pricing. This table does not take into account further dilution to new investors that could occur upon the exercise of outstanding options and warrants having a per share exercise price less than the public offering price per share in this offering.

 

If the underwriters exercise in full their option to purchase up to ____ additional shares of common stock and Series A Warrants at the assumed initial public offering price of $____ per share, the as adjusted net tangible book value (deficit) after this offering would be $____ per share, representing an increase in net tangible book value (deficit) of $____ per share to existing shareholders and immediate dilution in net tangible book value (deficit) of $____ per share to investors purchasing our common shares in this offering at the assumed public offering price.

 

24
 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FISCAL CONDITION AND RESULTS OF OPERATION

 

The following discussion of our plan of operation should be read in conjunction with the financial statements and related notes that appear elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in “Risk Factors” beginning on page 6 of this prospectus. All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.

 

We are an emerging growth company as defined in Section 2(a)(19) of the Securities Act. Pursuant to Section 107 of the Jumpstart Our Business Startups Act, we may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards, meaning that we can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have chosen to take advantage of the extended transition period for complying with new or revised accounting standards applicable to public companies to delay adoption of such standards until such standards are made applicable to private companies. Accordingly, our consolidated financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards.

 

Our Company

 

Sigyn Therapeutics, Inc. (“Sigyn”, the “Company” “we,” “us,” or “our”) is a development-stage company focused on addressing unmet needs in global health. Sigyn Therapy™ is a broad-spectrum blood purification technology designed to reduce the presence of viral pathogens, bacterial toxins, and inflammatory mediators from the bloodstream.

 

Candidate treatment indications for Sigyn Therapy include endotoxemia and inflammation in End-Stage Renal Disease (ESRD) dialysis patients, Sepsis (leading cause of hospital deaths worldwide1), Community Acquired Pneumonia (a leading cause of death among infectious diseases2) and Emerging Bioterror and Pandemic threats.

 

Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have filed patent and trademark submissions related to a therapeutic system to enhance the delivery of cancer chemotherapy and reduce its toxicity. At present, we have no market approved medical products.

 

1Global, regional and national sepsis incidence and mortality The Journal Lancet, January 2020  

 

2The American Thoracic Society – Pneumonia Facts 2019

 

Financing Transactions

 

Preferred Stock

 

The Company has 10,000,000 shares of par value $0.0001 preferred stock authorized, of which no preferred shares are issued and outstanding at December 22, 2022.

 

Common Stock

 

The Company has authorized 1,000,000,000 shares of par value $0.0001 common stock, of which 37,295,813 shares were outstanding as of December 22, 2022.

 

On October 28, 2021, an investor elected to convert $16,714 of the aggregate principal amount of the Note of $199,650, into 42,857 common shares.

 

On October 25, 2021, an investor elected to convert the aggregate principal amount of the Note, $110,000, into 157,143 common shares.

 

On October 20, 2021, the Company entered into a securities purchase agreement with an accredited investor that resulted in the issuance of 320,000 shares of common stock and warrants to purchase an aggregate of 320,000 shares of the Company’s common stock for total proceeds totaling $400,000. The offering allowed for qualified investors to purchase one share of the Company’s common stock at $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.25 per share. No commissions were paid in the offering. This issuance was pursuant to Section 4(a)(2) of the Securities Act in a transaction exempt from registration.

 

25
 

 

On October 14, 2021, the Company issued a total of 47,000 shares of its common stock valued at $37,600 (based on the stock price of the Company’s common stock on the date of issuance) to a third party, for communications to the financial industry.

 

On July 14, 2021, the Company issued a total of 47,000 shares of its common stock valued at $47,000 (based on the stock price of the Company’s common stock on the date of issuance) to a third party, for communications to the financial industry.

 

On May 10, 2021, Brio Capital elected to convert the aggregate principal amount of a $110,000 convertible note issued on February 10, 2021 into 157,143 shares of the Company’s common stock.

 

In April 2021, the Company initiated an offering of up to $1.5 million of the Company’s restricted common shares. The offering allowed for qualified investors to purchase one share of the Company’s common stock $1.25. For each share purchased, the investor received a five-year warrant to purchase one share of common stock at $1.75 per share. On May 10, 2021, the Company closed the offering to investors and subsequently disclosed that it had entered into securities purchase agreements with accredited investors that resulted in the issuance of 1,172,000 shares of common stock and warrants to purchase an aggregate of 1,172,000 shares of the Company’s common stock for total proceeds totaling $1,465,000. No commissions were paid in the offering. This issuance was pursuant to Section 4(a)(2) of the Securities Act in a transaction exempt from registration.

 

On April 14, 2021, the Company issued a total of 47,000 shares of its restricted common stock valued at $82,250 (based on the stock price of the Company’s common stock on the date of issuance) to a third party, for communications to the financial industry. This issuance was pursuant to Section 4(a)(2) of the Securities Act in a transaction exempt from registration.

 

On February 19, 2021, a previous noteholder exercised the warrants pursuant to the cashless exercise provision of the warrant agreement into 57,147 common shares. The common shares have not been issued as of March 14, 2022.

 

On January 14, 2021, the Company issued a total of 47,000 shares of its restricted common stock valued at $82,250 (based on the stock price of the Company’s common stock on the date of issuance) to a third party, for communications to the financial industry. This issuance was pursuant to Section 4(a)(2) of the Securities Act in a transaction exempt from registration.

 

During the year ended December 31, 2020, the Company issued 1,015,344 common shares to third parties in conjunction with the exchange of convertible promissory debentures.

 

On October 19, 2020, the Company issued 33,686,169 common shares in conjunction with the Acquisition.

 

Warrants

 

On October 22, 2021, the Company and Osher amended convertible debt agreements for the maturity date from October 20, 2021 to October 20, 2022. In exchange for the extension of the Note, the Company issued Osher 450,000 warrants to purchase an aggregate of 450,000 shares of the Company’s common stock, valued at $197,501 (based on the Black Scholes valuation model on the date of grant) (see Note 6). The warrants are exercisable for a period of five years at $1.00 per share in whole or in part, as either a cash exercise or as a cashless exercise, and fully vest at grant date. The Company is amortizing the value of the warrants ratably through October 20, 2022. The Company recorded $40,041 and $0 for the years ended December 31, 2021 and 2020, respectively, and is classified in other expenses in the consolidated Statements of Operations.

 

Current Noteholders

 

Osher – $457,380

 

On January 28, 2020, the Company entered into a Securities Purchase Agreement with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $385,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture due January 26, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants to purchase up to an aggregate of 80,209 shares of the Company’s common stock at an exercise price of $7.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the note and warrants was $350,005 which was issued at a $34,995 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.094 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

26
 

 

The Company and Osher amended the convertible debt agreement as follow-on October 20, 2020:

 

The parties amended the Warrants dated January 28, 2020, for the number of warrant shares from 80,209 warrant shares to 4,113,083 warrant shares at an exercise price of $0.14 per share.
The parties amended the Note for the maturity date from June 23,2021 to October 20, 2021.

 

On October 22, 2021, the Company and Osher amended convertible debt agreements as follows:

 

The parties amended the October 20,2020 Notes for the maturity date from October 20, 2021 to October 20, 2022.
The parties amended the October 20,2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022.
In exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 450,000 shares of the Company’s common stock at an exercise price of $1.00 per share.

 

The Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to restructure the terms of the note.

 

Osher – $60,500

 

On June 23, 2020, the Company entered into a Securities Purchase Agreement with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due June 23, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 10,000 shares of the Company’s Common Stock at an exercise price of $30.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at a $0 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

The Company and Osher amended the convertible debt agreement as follow-on October 20, 2020:

 

The parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at an amended $4,995 original issue discount from the face value of the Note.
The parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 10,000 warrant shares to 141,020 warrant shares at an exercise price of $0.59 per share.
The parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021.

 

On October 22, 2021, the Company and Osher amended convertible debt agreements as follows:

 

The parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022.
The parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022.
In exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 450,000 shares of the Company’s common stock at an exercise price of $1.00 per share.

 

The Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to restructure the terms of the note.

 

Osher – $199,650

 

On September 17, 2020, the Company entered into a Securities Purchase Agreement with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $181,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due September 30, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 8,250 shares of the Company’s Common Stock at an exercise price of $30.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $165,000 which was issued at a $16,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.39 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

27
 

 

The Company and Osher amended the convertible debt agreement as follow-on October 20, 2020:

 

The parties amended the Warrants dated September 17, 2020, for the number of warrant shares from 8,250 warrant shares to 465,366 warrant shares at an exercise price of $0.59 per share.
The parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021.

 

On October 22, 2021, the Company and Osher amended convertible debt agreements as follows:

 

The parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022.
The parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022.
In exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 450,000 shares of the Company’s common stock at an exercise price of $1.00 per share.

 

On October 28, 2021, Osher elected to convert $16,714 of the aggregate principal amount of the Note of $199,650, into 42,857 common shares.

 

The Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to restructure the terms of the note.

 

Osher – $110,000

 

On March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 220,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.50 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Brio – $110,000

 

On March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 220,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.50 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Osher – $110,000

 

On April 28, 2022, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “Note”) totaling (i) $220,000 aggregate principal amount of Note due April 28, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 440,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The conversion price for the principal in connection with voluntary conversions by the holders of the convertible notes is $0.50 per share.

 

Brio - $110,000

 

On May 10, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “May 2022 Note”) totaling (i) $110,000 aggregate principal amount of Note due May 10, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 220,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The conversion price for the principal in connection with voluntary conversions by the holders of the convertible notes is $0.50 per share.

 

28
 

 

Osher – $55,000

 

On June 1, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal amount of Note due June 1, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 110,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $50,000 which was issued at a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.50 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Osher – $82,500

 

On June 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $82,500 aggregate principal amount of Note due June 22, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 165,000 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.50 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Other – $341,000

 

In July 2022, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “July 2022 Notes”) totaling (i) $341,000 aggregate principal amount of Note (total of $310,000 cash was received) due in various dates in July 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 676,936 shares of the Company’s Common Stock at an exercise price of $0.50 per share. The conversion price for the principal in connection with voluntary conversions by the holders of the convertible notes is $0.50 per share.

 

Osher – $110,000

 

On August 31, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal amount of Note due August 31, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 733,333 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Brio – $82,500

 

On September 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $82,500 aggregate principal amount of Note due September 9, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 550,000 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Osher – $110,000

 

On September 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal amount of Note due September 20, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 733,333 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

29

 

 

Impairment of Inventory

 

Based on the significant advancement of Sigyn Therapy, the Company decided in the 4th quarter of 2021 to assess the value of retail business operations that were a focus of the Company prior to the merger transaction consummated on October 19, 2020.

 

Related to this assessment, management determined the wholesale liquidation value of its sapphire gem inventory to be 5-10% of the previously reported retail value, based on communications with certified gemologists, the variance between retail and wholesale valuations, and current market conditions. As a result, the Company has valued the inventory at $50,000 and recorded an impairment of assets of $536,047 in the year ended December 31, 2021 and is classified in other expenses in the consolidated Statements of Operations.

 

Limited Operating History; Need for Additional Capital

 

There is limited historical financial information about us on which to base an evaluation of our performance. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, and possible cost overruns due to increases in the cost of services. To become profitable and competitive, we must receive additional capital. We have no assurance that future financing will materialize. If that financing is not available, we may be unable to continue operations.

 

Results of Operations - Year Ended December 31, 2021 Compared to Year Ended December 31, 2020

 

The following discussion represents a comparison of our results of operations for the years ended December 31, 2021 and 2020. The results of operations for the periods shown in our audited consolidated financial statements are not necessarily indicative of operating results for the entire period. In the opinion of management, the audited consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state our financial position, results of operations and cash flows for the periods presented.

 

   Year Ended December 31, 2021   Year Ended December 31, 2020 
         
Net revenues   $-   $ -   
Cost of sales    -    - 
Gross Profit    -    - 
Operating expenses    2,008,217    916,434 
Other expense    996,402    343,156 
Net loss before income taxes   $(3,004,619)  $(1,259,590)

 

Net Revenues

 

For the years ended December 31, 2021 and 2020, we had no revenues.

 

Cost of Sales

 

For the years ended December 31, 2021 and 2020, we had no cost of sales.

 

Operating expenses

 

Operating expenses increased by $1,091,783, or 119.1%, to $2,008,217 for the year ended December 31, 2021 from $916,434 for the year ended December 31, 2020 primarily due to increases in professional fees of $36,211, compensation costs of $259,154, consulting costs of $112,919, research and development costs of $314,652, depreciation and amortization costs of $7,851, investor relations costs of $306,487, rent expenses of $45,154, and general and administration costs of $9,355, as a result of adding administrative infrastructure for our anticipated business development. In 2021, the Company has incurred an increase in professional fees (primarily audit fees), incurred a full year of compensation for its CEO and CTO and hired a Director of Operations resulting in increased compensation costs, increased consulting costs (primarily for public relations and brand awareness), has increased investor relations costs (primarily the fair value of common stock issued for services), and increased rent through the lease of office space in June 2021. Research and development costs consist of an increase of $175,842 attributed to in house efforts and $138,810 to third parties for developmental services and testing.

 

For the year ended December 31, 2021, we had research and development costs of $734,014, and general and administrative expenses of $1,274,203 primarily due to professional fees of $123,293, compensation costs of $451,734, consulting costs of $286,194, rent of $46,663, depreciation and amortization costs of $19,151, investor relations costs of $329,006, and general and administration costs of $18,162. In 2021, the Company has incurred professional fees (primarily legal and audit fees), incurred a full year of compensation for its CEO and CTO and hired a Director of Operations, incurred consulting costs (primarily for public relations and brand awareness), had investor relations costs (primarily the fair value of common stock issued for services), and had rent through the lease of office space in June 2021. Research and development costs consist of $567,748 attributed to in house efforts and $166,266 to third parties for developmental services and testing.

 

For the year ended December 31, 2020, we had marketing expenses of $705, research and development costs of $419,362, and general and administrative expenses of $496,367 primarily due to professional fees of $260,356, compensation costs of $192,580, rent of $1,509, depreciation and amortization costs of $11,300, investor relations costs of $22,519, and general and administration costs of $8,103. In 2020, the Company has incurred professional fees (primarily legal and audit fees, and consulting costs), and incurred compensation for its CEO and CTO. Research and development costs consist of $391,906 attributed to in house efforts and $27,456 to third parties for developmental services and testing.

 

30

 

 

 

Net loss before income taxes

 

Net loss before income taxes for the year ended December 31, 2021 totaled $3,004,619 primarily due to (increases/decreases) in compensation costs, professional fees, consulting costs, research and development costs, investor relations costs, and general and administration costs compared to a loss of $1,259,590 primarily due to (increases/decreases) in compensation costs, professional fees, marketing costs, research and development costs, investor relations costs, and general and administration costs for the year ended December 31, 2020 primarily due to professional fees.

 

Assets and Liabilities

 

Assets were $710,259 as of December 31, 2021. Assets consisted primarily of cash of $340,956, inventories of $50,000, equipment of $28,046, intangible assets of $5,700, and operating lease right-of-use assets of $262,771. Liabilities were $974,843 as of December 31, 2021. Liabilities consisted primarily accounts payable of $39,674, accrued payroll and payroll taxes of $1,072, convertible notes of $647,202, net of $53,614 of unamortized debt discount, operating lease liabilities of $286,716, and other current liabilities of $179.

 

Liquidity and Capital Resources

 

General – Overall, we had an increase in cash flows for the year ended December 31, 2021 of $256,554 resulting from cash provided by financing activities of $2,060,000, offset partially by cash used in operating activities of $1,774,182 and cash used in investing activities of $29,264.

 

The following is a summary of our cash flows provided by (used in) operating, investing, and financing activities during the periods indicated:

 

   Year Ended December 31, 2021   Year Ended December 31, 2020 
         
Net cash provided by (used in):          
Operating activities  $(1,774,182)  $(829,809)
Investing activities   (29,264)   (10,799)
Financing activities   2,060,000    925,010 
   $256,554   $84,402 

 

Cash Flows from Operating Activities – For the year ended December 31, 2021, net cash used in operations was $1,774,182 compared to net cash used in operations of $829,809 for the year ended December 31, 2020. Net cash used in operations was primarily due to a net loss of $3,004,619 for year ended December 31, 2021 and the changes in operating assets and liabilities of $34,149, primarily due to the increases in other current assets of $2,075 and other assets of $20,711, and a decrease in accrued payroll and payroll taxes of $58,635, offset primarily by increases in accounts payable of $23,669 and other current liabilities of $23,603. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $2,946, amortization expense of $16,205, accretion of original issuance costs of $61,283, accretion of debt discount of $368,205, stock issued for services of $249,100, interest expense converted to notes payable of $30,800, and impairment of assets of $536,047.

 

31

 

 

Net cash used in operations was primarily due to a net loss of $1,259,590 for year ended December 31, 2020 and the changes in operating assets and liabilities of $75,325, primarily due to the increase in accounts payable of $15,095, accrued payroll and payroll taxes of $59,707, and other current liabilities of $523. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $346, amortization expense of $10,954, accretion of original issuance costs of $67,823, and accretion of debt discount of $275,333.

 

Cash Flows from Investing Activities – For the year ended December 31, 2021, net cash used in investing was $29,264 due to the purchase of property and equipment compared to cash flows from investing activities of $10,799 due to the purchase of intangible assets for the year ended December 31, 2020.

 

Cash Flows from Financing Activities – For the year ended December 31, 2021, net cash provided by financing was $2,060,000 due to proceeds from short term convertible notes of $250,000, repayments of short-term convertible notes of $55,000, and common stock and warrants issued for cash of $1,865,000. For the year ended December 31, 2020, net cash provided by financing was $925,010 due to proceeds from short term convertible notes.

 

Financing – We expect that our current working capital position, together with our expected future cash flows from operations will be insufficient to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject to numerous risks, and there can be no assurance that we will not require additional funding in the future.

 

We have no present agreements or commitments with respect to any material acquisitions of other businesses, products, product rights or technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Due to the ongoing global economic crisis, we believe it may be difficult to obtain additional financing if needed. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing.

 

Going Concern

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of approximately $4,266,000 at December 31, 2021, had a working capital deficit of approximately $341,000 at December 31, 2021, had net losses of approximately $3,005,000 and $1,260,000 for the years ended December 31, 2021 and 2020, respectively, and net cash used in operating activities of approximately $1,774,000 and $830,000 for the years ended December 31, 2021 and 2020, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a private offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

 

The consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Critical Accounting Policies

 

Refer to Note 3 in the accompanying notes to the unaudited condensed consolidated financial statements for critical accounting policies.

 

Recent Accounting Pronouncements

 

Refer to Note 3 in the accompanying notes to the unaudited condensed consolidated financial statements.

 

32

 

 

Off-Balance Sheet Arrangements

 

As of December 31, 2021, we had not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated under which it has:

 

  a retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit;
  liquidity or market risk support to such entity for such assets;
  an obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument; or
 

an obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by, and material to us, where such entity provides financing, liquidity, market risk or credit risk support to or engages in leasing, hedging, or research and development services with us.

  

Recent Developments

 

Convertible Promissory Debentures

 

Osher – $110,000

 

On October 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal amount of Note due October 20, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 733,333 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Brio – $82,500

 

On November 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $82,500 aggregate principal amount of Note due November 9, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 550,000 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Osher – $55,000

 

On November 14, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal amount of Note due November 14, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 366,667 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $50,000 which was issued at a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

Osher – $145,200

 

On November 21, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $145,200 aggregate principal amount of Note due November 21, 2023 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants’) to purchase up to an aggregate of 968,000 shares of the Company’s Common Stock at an exercise price of $0.25 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance of the Note and Warrants was $132,000 which was issued at a $13,200 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.

 

On November 23, 2022, the noteholder elected to convert the aggregate principal amount of the Note, $145,200, into 968,000 common shares.

 

33

 

 

Limited Operating History; Need for Additional Capital

 

There is limited historical financial information about us on which to base an evaluation of our performance. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, and possible cost overruns due to increases in the cost of services. To become profitable and competitive, we must receive additional capital. We have no assurance that future financing will materialize. If that financing is not available, we may be unable to continue operations.

 

Business Overview

 

Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) is a development-stage medical technology company headquartered in San Diego, California. We are focused on creating therapeutic solutions that address unmet needs in global health.

 

We are developing Sigyn Therapy™ as a candidate to treat life-threatening infections and inflammatory disorders for which effective drug therapies are not available. We designed Sigyn Therapy to reduce the circulating presence of pathogen sources of life-threatening inflammation in concert with dampening down the dysregulated overproduction of inflammatory cytokines (the cytokine storm), which plays a prominent role in each of our candidate treatment indications.

 

We are advancing Sigyn Therapy as a candidate to treat end-stage renal disease (ESRD) dialysis patients with chronic inflammation and/or endotoxemia, pathogen-associated sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats.

 

Since initiating the development of Sigyn Therapy in 2020, we completed pre-clinical in vitro studies that quantified the reduction of pathogen sources of inflammation from human blood plasma with small-scale versions of Sigyn Therapy. These include endotoxin (a gram-negative bacterial toxin), peptidoglycan and lipoteichoic acid (gram-positive bacterial toxins), and viral pathogens, including COVID-19.

 

We also completed in vitro studies that quantified the reduction of inflammatory cytokines from human blood plasma with small-scale versions of Sigyn Therapy. These include interleukin-1 beta (IL-1b), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-a). In a related study, liposomes were reduced from human blood plasma as a model system to evaluate the potential of Sigyn Therapy to target CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream.

 

In vitro studies also quantified the reduction of hepatic (liver) toxins from human blood plasma with small-scale versions of Sigyn Therapy. These included ammonia, bile acid and bilirubin. Based on these outcomes, we may further investigate the potential of Sigyn Therapy to treat acute forms of liver failure in future studies.

 

Each of our in vitro studies were conducted by Innovative Biotherapies, based in Ann Arbor, Michigan. With the exception of the liposome data results, the studies quantified the reduction of each target from human blood plasma with small-scale versions of Sigyn Therapy. Each of these studies were conducted for a period of four hours. In the liposome study, the formulation of adsorbent components that we incorporate within Sigyn Therapy was quantified to reduce the presence of liposomes from human blood plasma in a test-tube rocker study conducted for a period of two hours. While we maintain ownership of our in vitro study results, we do provide rights to researchers at Innovative Biotherapies to publish our study results.

 

Subsequent to our in vitro study results, we completed in vivo animal studies of Sigyn Therapy at the University of Michigan. In these studies, Sigyn Therapy was administered via standard dialysis machines utilizing conventional blood-tubing sets, for periods up to six hours in eight porcine (pig) subjects. Important criteria for treatment feasibility, including hemodynamic parameters, serum chemistries and hematologic measurements, were stable across all eight subjects. While we maintain ownership of our in vivo animal study data, we do provide rights to researchers at the University of Michigan to publish the results of our animal studies.

 

The data resulting from our in vivo and in vitro studies is being incorporated into an Investigational Device Exemption (IDE) that we are drafting for submission to the U.S. Food and Drug Administration (“FDA”) to support the potential initiation of human feasibility studies in the United States.

 

34
 

 

Sigyn Therapy Mechanism of Action

 

We are advancing Sigyn Therapy as a candidate to treat pathogen-associated conditions that precipitate Sepsis, Community Acquired Pneumonia, Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease patients with endotoxemia and elevated inflammatory cytokine production.

 

To support widespread implementation, Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines already located in hospitals and clinics. To reduce the risk of blood clotting and hemolysis, the anticoagulant heparin is administered, which is the standard-of-care drug administered in dialysis and CRRT therapies. During animal studies conducted at the University of Michigan, Sigyn Therapy was deployed for use on a hemodialysis machine manufactured by Fresenius Medical Care, the global leader in the dialysis industry.

 

Incorporated within Sigyn Therapy is a “cocktail” of adsorbent components formulated to optimize the reduction of therapeutic targets from the bloodstream. In the medical field, the term “cocktail” is a reference to the simultaneous administration of multiple drugs (a drug cocktail) with differing mechanisms of actions. While drug cocktails are emerging as potential mechanisms to treat cancer, they are life-saving countermeasures to treat HIV and Hepatitis-C viral infections. However, dosing of multi-drug agent cocktails is limited by toxicity and adverse events that can result from deleterious drug interactions.

 

Sigyn Therapy is not constrained by such limitations as active adsorbent components are maintained within Sigyn Therapy and not introduced into the body. As a result, we are able to incorporate a substantial quantity of adsorbent components to capture therapeutic targets outside of the body as they circulate through Sigyn Therapy. Each adsorbent component has differing capture characteristics that contribute to reducing the circulating presence of pathogenic and inflammatory targets that precipitate the cytokine storm that underlies sepsis and other life-threatening inflammatory disorders.

 

The adsorbent components incorporated within Sigyn Therapy provide more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove circulating viruses, bacterial toxins, and inflammatory mediators. Based on targeted blood flow rates of 350ml/min, a patient’s entire bloodstream can pass through Sigyn Therapy more than fifteen times during a single four-hour treatment period.

 

From a technical perspective, Sigyn Therapy is a 325 mm long polycarbonate column that internally contains polyethersulphone hollow fibers that have porous walls have a median pore size of ~200 nanometers (nm). As blood flows into Sigyn Therapy, plasma and therapeutic targets below 200nm travel through the porous walls as a result of blood-side pressure. As the hollow fiber bundle within Sigyn Therapy creates a resistance to the flow of blood, a pressure drop is created along the length of the device such that the blood-side pressure is higher at the blood inlet and lower at the blood outlet. This allows for plasma and therapeutic targets to flow away from the blood and into the extra-lumen space (inside the polycarbonate shell, yet outside the hollow-fiber bundle) to interact with Sigyn Therapy’s adsorbent components in a low shear force environment. In the distal third of the fiber bundle, the pressure gradient is reversed, which allows for plasma to flow back through the fiber walls to be reconvened into the bloodstream without the presence of therapeutic targets that were captured by adsorbent components housed in the extra-lumen space of Sigyn Therapy.

 

Overview of Candidate Treatment Indications

 

Based on data resulting from in vitro blood purification studies, our candidate treatment indications include, but are not limited to; pathogen-associated conditions that precipitate Sepsis (leading cause of hospital deaths worldwide), Community Acquired Pneumonia (a leading cause of death among infectious diseases), Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease (ESRD) patients with endotoxemia and elevated inflammatory cytokine production. However, there is no assurance that human feasibility and pivotal studies will demonstrate Sigyn Therapy to be a safe and efficacious treatment for any of our treatment indications.

 

35
 

 

End-Stage Renal Disease Endotoxemia and Inflammation

 

According to the United States Renal Data System (USRDS), more than 550,000 individuals suffer from end-stage renal disease (ESRD), which results in approximately 85 million kidney dialysis treatments being administered in the United States each year. Persistent inflammation is a hallmark feature of ESRD as reflected by the excess production of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), which contribute to increased all-cause mortality. ESRD inflammation also induces intestinal permeability, which allows endotoxin (gram-negative bacterial toxin) to translocate from the gut and into the bloodstream. Beyond fueling further inflammation, endotoxin is potent activator of sepsis, which can lead to multiple organ failure and death.

 

Sigyn Therapy establishes a candidate strategy to improve the health and quality-of-life of ESRD patients. Beyond its potential to reduce endotoxin, TNF-α, IL-1β, and IL-6 from human blood plasma, Sigyn Therapy can be administered in series with dialysis therapy.

 

We are currently drafting an Investigational Device Exemption (IDE) for submission to the U.S. Food and Drug Administration (“FDA”) related to a human feasibility study of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients with endotoxemia and elevated inflammatory cytokine production. As per the study protocol, Sigyn Therapy will be administered in combination with the regularly scheduled dialysis treatments of enrolled subjects. The primary study objective will be to evaluate the safety of Sigyn Therapy in health compromised ESRD patients. A secondary objective is to quantify changes in circulating levels of endotoxin, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) before and after each Sigyn Therapy administration. Endotoxin and excess TNF-α, IL-1β, and IL-6 production are commonly associated with each of our candidate treatment indications, including sepsis and community-acquired pneumonia.

 

Sepsis

 

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In January of 2020, a report entitled; “Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study,” was published in the Journal Lancet. The publication reported 48.9 million cases of sepsis and 11 million deaths in 2017. In that same year, an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5-years old. The report included a reference that sepsis kills more people around the world than all forms of cancer combined. In the United States, sepsis was reported to be the most common cause of hospital deaths with an annual financial burden that exceeds $24 billion.

 

To date, more than 100 human studies have been conducted to evaluate the safety and efficacy of candidate drugs to treat sepsis. With one brief exception (Xigris, Eli Lilly), none of these studies resulted in a market cleared therapy.

 

As sepsis remains beyond the reach of single-target drugs, there is an emerging interest in multi-mechanism therapies that can target both inflammatory and pathogen associated targets. Sigyn Therapy addresses a broad-spectrum of pathogen sources and the resulting dysregulated cytokine production (the cytokine storm) that is the hallmark of sepsis. Additionally, we believe that inflammatory cytokine cargos transported by CytoVesicles may represent a novel, yet important therapeutic target.

 

Community Acquired Pneumonia

 

Community Acquired Pneumonia (CAP) represents a significant opportunity for Sigyn Therapy to reduce the occurrence of sepsis. CAP is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.

 

In the United States, more than 1.5 million individuals are hospitalized with CAP each year, resulting in an annual financial burden that exceeds $10 billion.

 

Statistically, a therapeutic strategy that reduced the incidence of CAP related sepsis and septic shock would save thousands of lives each year. In a study of 4,222 patients, the all-cause mortality for adult patients with CAP was reported to be 6.5% during hospitalization. However, the mortality of patients with CAP related sepsis and septic shock rose to 51% during hospitalization.

 

CAP is further complicated by the fact that the pathogen sources of CAP are identified in only 38% of patients, based on a study of 2,259 subjects whose pneumonia diagnosis was confirmed by chest x-ray. Of the source pathogens identified in the study, ninety seven percent (97%) were either viral or bacterial in origin.

 

To reduce the occurrence of CAP related sepsis and septic shock, Sigyn Therapy offers a broad-spectrum mechanism to reduce the circulating presence of viral pathogens and bacterial toxins before and if they are identified as the CAP pathogen source. Additionally, Sigyn Therapy may help to control the excess production of inflammatory cytokines (the cytokine storm) that precipitate sepsis and septic shock.

 

36
 

 

Emerging Pandemic Threats

 

Covid-19 affirmed the use of extracorporeal blood purification as a first-line countermeasures to treat an emerging pandemic threat not addressed with an approved drug or vaccine at the outset of an outbreak. On March 24, 2020, the U.S. Department of Health and Human Services (HHS) declared that the emergence of COVID-19 justified the Emergency-Use Authorization (EUA) of drugs, biological products, and medical devices to combat the pandemic. Within a month of this HHS declaration, FDA awarded an EUA to blood purification therapies from Terumo BCT, ExThera Medical Corporation, CytoSorbents, Inc., and Baxter Healthcare Corporation. In connection with these authorizations, FDA published a statement that blood purification devices may be effective at treating patients with confirmed COVID-19 by reducing various pathogens, cytokines, and other inflammatory mediators from the bloodstream.

 

Consistent with FDA’s statement, Sigyn Therapy has reduced various pathogens, cytokines, and other inflammatory mediators from human blood plasma during in vitro studies and may represent a candidate strategy to treat future pandemic outbreaks, which are increasingly being fueled by a confluence of global warming, urban crowding, and intercontinental travel.

 

Additionally, as a majority of infectious human viruses are not addressed with a corresponding drug or vaccine, there may be an ongoing need for blood purification technologies that offer to reduce the severity of infection and mitigate the excess production of inflammatory cytokines (the cytokine storm) associated with high mortality in non-pandemic viral infections. In this regard, we believe Sigyn Therapy also aligns with HHS initiatives established through the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) that support the development of broad-spectrum medical countermeasures that can mitigate the impact of an emerging pandemic or bioterror threat, yet also have viability in established disease indications.

 

Candidate Pipeline Product

 

Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have designed a therapeutic system to enhance the benefit of cancer chemotherapy. To support this endeavor, we disclosed on October 6, 2022, that a patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” had been filed with the United States Patent and Trademark Office (“USPTO”). On October 13, 2022, we subsequently disclosed that trademark applications to register ChemoPrepTM and ChemoPureTM were filed with the USPTO”.

 

Chemotherapeutic agents are the most commonly administered drugs to treat cancer, which is the second leading cause of death in the United States.

 

Despite therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy. To overcome these challenges, our patent submission describes a therapeutic device system whose primary objective is to enhance tumor site delivery of chemotherapy and reduce its toxicity. A secondary objective of the system is to reduce treatment dosing without sacrificing patient benefit, or conversely increase chemotherapy dosing without added toxicity. In concert with these objectives, the therapeutic system offers to inhibit the spread of cancer metastasis reported to be induced by the administration of chemotherapy.

 

Our proposed chemotherapy enhancement system is comprised of two blood purification technologies. ChemoPrepTM, administered prior to chemotherapy to optimize tumor site delivery and improve the benefit of ChemoPureTM, which is deployed post-chemotherapy to reduce treatment toxicity and inhibit the potential spread of cancer metastasis.

 

Overview of Presentation

 

The following Management’s Discussion and Analysis (“MD&A”) or Plan of Operations includes the following sections:

 

Results of Operations
   
Liquidity and Capital Resources
   
Capital Expenditures
   
Going Concern
   
Critical Accounting Policies
   
Off-Balance Sheet Arrangements

 

General and administrative expenses consist primarily of personnel costs and professional fees required to support our operations and growth.

 

Depending on the extent of our future growth, we may experience significant strain on our management, personnel, and information systems. We will need to implement and improve operational, financial, and management information systems. In addition, we are implementing new information systems that will provide better record-keeping, customer service and billing. However, there can be no assurance that our management resources or information systems will be sufficient to manage any future growth in our business, and the failure to do so could have a material adverse effect on our business, results of operations and financial condition.

 

Reclassifications

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Operations for three months ended March 31, 2021, to reclass $93,266 of costs to research and development previously classified in general and administrative. In addition, an adjustment has been made to the Unaudited Condensed Consolidated Balance Sheets as of December 31, 2021, to reclass $1,072 of other current liabilities previously classified in accrued payroll and payroll taxes.

 

37
 

 

Results of Operations

 

Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021

 

The following discussion represents a comparison of our results of operations for the three months ended September 30, 2022 and 2021. The results of operations for the periods shown in our audited condensed consolidated financial statements are not necessarily indicative of operating results for the entire period. In the opinion of management, the audited condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state our financial position, results of operations and cash flows for the periods presented.

 

   Three Months Ended September 30, 
   2022   2021 
         
Net revenues  $-   $- 
Cost of sales   -    - 
Gross Profit   -    - 
Operating expenses   533,647    573,363 
Other expense   192,682    92,541 
Net loss before income taxes and discontinued operations  $(726,509)  $(649,861)

 

Net Revenues

 

For the three months ended September 30, 2022 and 2021, we had no revenues.

 

Cost of Sales

 

For the three months ended September 30, 2022 and 2021, we had no cost of sales as we had no revenues.

 

Operating expenses

 

Operating expenses decreased by $39,716, or 6.9%, to $533,647 for three months ended September 30, 2022 from $573,363 for the three months ended September 30, 2021 primarily due to decreases in research and development costs of $93,733, investor relations costs of $49,835, consulting fees of $40,048, and rent expenses of $4,413, offset primarily by increases in compensation costs of $54,994, professional fees of $16,428, depreciation costs of $1,283, marketing costs of $65, insurance costs of $78,852, and general and administration costs of $3,309, as a result of adding administrative infrastructure for our anticipated business development. In 2022, the Company incurred compensation for its CEO and CTO and hired a CFO resulting in increased compensation costs, has increased professional fees (primarily legal), and has decreased investor relations costs (primarily the fair value of common stock issued for services of $47,000 in 2021). Research and development costs consist of a decrease of $45,944 attributed to in house efforts and a decrease of $47,789 to third parties for developmental services and testing.

 

For the three months ended September 30, 2022, we had marketing expenses of $65, research and development costs of $133,770, and general and administrative expenses of $399,812 primarily due to professional fees of $40,729, compensation costs of $192,315, insurance expense of $78,852, rent of $19,999, depreciation costs of $1,715, amortization costs of $900, investor relations costs of $19,474, consulting fees of $41,775, and general and administration costs of $4,053, as a result of adding administrative infrastructure for our anticipated business development. In 2022, the Company incurred professional fees (primarily legal and audit fees), incurred compensation for its CEO and CTO and hired a CFO, incurred consulting costs (primarily for public relations and brand awareness), had investor relations costs, and had rent through the lease of office space. Research and development costs consist of $131,900 attributed to in house efforts and $1,870 to third parties for developmental services and testing.

 

For the three months ended September 30, 2021, we had research and development costs of $227,503, and general and administrative expenses of $345,860 primarily due to professional fees of $24,301, compensation costs of $137,321, rent of $24,412, depreciation and amortization costs of $1,332, investor relations costs of $69,309, consulting fees of $81,823, and general and administration costs of $7,362, as a result of adding administrative infrastructure for our anticipated business development. In 2021, the Company incurred marketing costs (primarily the fair value of common stock issued for services), has incurred professional fees (primarily legal and audit fees, and consulting costs), incurred compensation for its CEO and CTO, incurred consulting costs (primarily for public relations and brand awareness), had investor relations costs (primarily the fair value of common stock issued for services of $47,000 in 2021), and had rent through the lease of office space beginning in June 2021. Research and development costs consist of $177,844 attributed to in house efforts and $49,659 to third parties for developmental services and testing.

 

38
 

 

Other Expense

 

Other expense for the three months ended September 30, 2022 totaled $192,862 primarily due to interest expense of $148,372 in conjunction with accretion of debt discount and interest expense of $44,420 in conjunction with accretion of original issuance discount, compared to other expense of $92,541 for the three months ended September 30, 2021 primarily due to interest expense of $49,749 in conjunction with accretion of debt discount and interest expense of $13,697 in conjunction with accretion of original issuance discount.

 

Net loss before income taxes

 

Net loss before income taxes and discontinued operations for the three months ended September 30, 2022 totaled $726,509 primarily due to (increases/decreases) in compensation costs, professional fees, marketing costs, investor relations costs, consulting fees, research and development costs, rent, and general and administration costs compared to a loss of $665,904 for the three months ended September 30, 2021 primarily due to (increases/decreases) in compensation costs, professional fees, investor relations, consulting fees, research and development costs, rent, and general and administration costs.

 

Assets and Liabilities

 

Assets were $362,273 as of September 30, 2022. Assets consisted primarily of cash of $28,123, inventories of $50,000, other current assets of $7,254, equipment of $23,767, intangible assets of $3,000, operating lease right-of-use assets of $229,418, and other assets of $20,711. Liabilities were $2,104,375 as of September 30, 2022. Liabilities consisted primarily of accounts payable of $306,000, accrued payroll and payroll taxes of $30,124, convertible notes of $1,515,443, net of $406,373 of unamortized debt discount and debt issuance costs, and operating lease liabilities of $252,808.

 

Nine Months Ended September 30, 2022 Compared to Nine Months Ended September 30, 2021

 

The following discussion represents a comparison of our results of operations for the nine months ended September 30, 2022 and 2021. The results of operations for the periods shown in our audited condensed consolidated financial statements are not necessarily indicative of operating results for the entire period. In the opinion of management, the audited condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state our financial position, results of operations and cash flows for the periods presented.

 

   Nine Months Ended September 30, 
   2022   2021 
         
Net revenues  $-   $- 
Cost of sales   -    - 
Gross Profit   -    - 
Operating expenses   1,675,677    1,417,278 
Other expense   395,203    360,169 
Net loss before income taxes and discontinued operations  $(2,070,880)  $(1,777,447)

 

39
 

 

Net Revenues

 

For the nine months ended September 30, 2022 and 2021, we had no revenues.

 

Cost of Sales

 

For the six months ended September 2022 and 2021, we had no cost of sales as we had no revenues.

 

Operating expenses

 

Operating expenses increased by $258,399, or 18.2%, to $1,675,677 for nine months ended September 30, 2022 from $1,417,278 for the nine months ended September 30, 2021 primarily due to increases in compensation costs of $199,796, professional fees of $73,893, research and development costs of $33,041, depreciation costs of $3,859, rent expenses of $27,905, and general and administration costs of $5,267, offset primarily by a decrease in marketing expenses of $164,054, consulting fees of $12,918, investor relations costs of $78,386, and amortization costs of $12,606, as a result of adding administrative infrastructure for our anticipated business development. In 2022, the Company has incurred an increase in professional fees (primarily legal and audit fees), incurred a full year of compensation for its CEO and CTO and hired a CFO resulting in increased compensation costs, increased consulting costs (primarily for public relations and brand awareness), has decreased investor relations costs (primarily the fair value of common stock issued for services of $211,500 in 2021), and incurred a full year of rent from the lease of office space in June 2021. Research and development costs consist of an increase of $46,618 attributed to in house efforts and a decrease of $13,577 to third parties for developmental services and testing.

 

For the nine months ended September 30, 2022, we had marketing expenses of $446, research and development costs of $516,796, and general and administrative expenses of $1,158,435 primarily due to professional fees of $172,170, compensation costs of $532,643, insurance expense of $182,689, rent of $56,590, depreciation and amortization costs of $7,839, investor relations costs of $43,465, consulting fees of $144,900, and general and administration costs of $18,139, as a result of adding administrative infrastructure for our anticipated business development. In 2022, the Company has incurred professional fees (primarily legal and audit fees), incurred compensation for its CEO and CTO and hired a CFO, incurred consulting costs (primarily for public relations and brand awareness), had investor relations costs, and had rent through the lease of office space. Research and development costs consist of $439,116 attributed to in house efforts and $77,680 to third parties for developmental services and testing.

 

For the nine months ended September 30, 2021, we had marketing expenses of $164,500, research and development costs of $483,755, and general and administrative expenses of $933,523 primarily due to professional fees of $98,277, compensation costs of $332,847, rent of $28,685, depreciation and amortization costs of $16,586, investor relations costs of $121,851, consulting fees of $157,818, and general and administration costs of $12,959, as a result of adding administrative infrastructure for our anticipated business development. In 2021, the Company has incurred professional fees (primarily legal and audit fees, and consulting costs), had investor relations costs (primarily the fair value of common stock issued for services of $211,500), and incurred compensation for its CEO and CTO. Research and development costs consist of $392,498 attributed to in house efforts and $91,257 to third parties for developmental services and testing.

 

40
 

 

Other Expense

 

Other expense for the nine months ended September 30, 2022 totaled $395,203 primarily due to interest expense of $309,226 in conjunction with accretion of debt discount and interest expense of $85,875 in conjunction with accretion of original issuance discount, compared to other expense of $360,169 for the nine months ended September 30, 2021 primarily due to interest expense of $286,391 in conjunction with accretion of debt discount and interest expense of $44,683 in conjunction with accretion of original issuance discount.

 

Net loss before income taxes

 

Net loss before income taxes and discontinued operations for the nine months ended September 30, 2022 totaled $2,070,880 primarily due to (increases/decreases) in compensation costs, professional fees, marketing costs, investor relations costs, consulting fees, research and development costs, rent, and general and administration costs compared to a loss of $1,777,447 for the nine months ended September 30, 2021 primarily due to (increases/decreases) in compensation costs, professional fees, investor relations, consulting fees, research and development costs, rent, and general and administration costs.

 

Liquidity and Capital Resources

 

Going Concern

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $6,336,639 at September 30, 2022, had a working capital deficit of $1,817,541 and $341,187 at September 30, 2022 and December 31, 2021, respectively, had a net loss of $726,609 and $2,070,880 and $665,904 and $1,777,447 for the three and nine months ended September 30, 2022 and 2021, respectively, and net cash used in operating activities of $1,378,475 and $1,221,221 for the nine months ended September 30, 2022 and 2021, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

 

The condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

General – Overall, we had a decrease in cash flows for the nine months ended September 30, 2022 of $312,833 resulting from cash used in operating activities of $1,378,475 and cash used in investing activities of $860, offset partially by cash provided by financing activities of $1,066,502.

 

The following is a summary of our cash flows provided by (used in) operating, investing, and financing activities during the periods indicated:

 

   Nine Months Ended September 30, 
   2022   2021 
         
Net cash provided by (used in):          
Operating activities  $(1,378, 475)  $(1,221,221)
Investing activities   (860)   (20,205)
Financing activities   1,066,502    1,660,000 
   $(312,833)  $418,574 

 

41
 

 

Cash Flows from Operating Activities – For the nine months ended September 30, 2022, net cash used in operations was $1,378,475 compared to net cash used in operations of $1,221,221 for the nine months ended September 30, 2021. Net cash used in operations was primarily due to a net loss of $2,070,880 for nine months ended September 30, 2022 and the changes in operating assets and liabilities of $289,465, primarily due to the increase in accounts payable of $266,147 and accrued payroll and payroll taxes of $29,052, offset partially by other current liabilities of $555 and other current assets of $5,179. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $5,139, amortization expense of $2,700, accretion of original issuance costs of $85,875, and accretion of debt discount of $309,226.

 

For the nine months ended September 30, 2021, net cash used in operations was $1,221,221. Net cash used in operations was primarily due to a net loss of $1,777,447 for nine months ended September 30, 2021 and the changes in operating assets and liabilities of $2,932, primarily due to the increase in accounts payable of $16,869 and other current liabilities of $43,692, offset primarily by other current assets of $27,509, other assets of $20,711, and accrued payroll and payroll taxes of $15,273. In addition, net cash used in operating activities includes adjustments to reconcile net profit from depreciation expense of $1,279, amortization expense of $15,305, stock issued for services of $211,500, accretion of original issuance costs of $44,683, and accretion of debt discount of $286,391.

 

Cash Flows from Investing Activities – For the nine months ended September 30, 2022, net cash used in investing activities was $860 due to the purchase of property and equipment compared to cash used in investing activities of $20,205 for the nine months ended September 30, 2021 due to the purchase of property and equipment.

 

Cash Flows from Financing Activities – For the nine months ended September 30, 2022, net cash provided by financing was $1,066,502, due to proceeds from short term convertible notes of $1,110,000 and fees associated with the filing of the Company’s Form S-1 of $43,498 compared to cash provided by financing activities of $1,660,000 for the nine months ended September 30, 2021 due to proceeds from common stock issued for cash of $1,465,000 and short term convertible notes $250,000, and repayment of short term convertible notes of $55,000.

 

Financing – We expect that our current working capital position, together with our expected future cash flows from operations will be insufficient to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. As stated above, Management intends to raise additional funds by way of a public offering or an asset sale transaction, however there can be no assurance that we will be successful in completing such transactions.

 

We have no present agreements or commitments with respect to any material acquisitions of other businesses, products, product rights or technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Due to the ongoing global economic crisis, we believe it may be difficult to obtain additional financing if needed. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

 

Capital Expenditures

 

We expect to purchase approximately $30,000 of equipment in connection with the expansion of our business during the next twelve months.

 

Fiscal year end

 

Our fiscal year end is December 31.

 

Critical Accounting Policies

 

Refer to Note 3 in the accompanying notes to the unaudited condensed consolidated financial statements for critical accounting policies.

 

42
 

 

Recent Accounting Pronouncements

 

Refer to Note 3 in the accompanying notes to the condensed consolidated financial statements.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2022, we had not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated under which it has:

 

a retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit;
   
liquidity or market risk support to such entity for such assets;
   
an obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument; or
   
an obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by, and material to us, where such entity provides financing, liquidity, market risk or credit risk support to or engages in leasing, hedging, or research and development services with us.

 

Inflation

 

We do not believe that inflation has had a material effect on our results of operations.

 

43
 

 

DESCRIPTION OF BUSINESS

 

Sigyn Therapeutics, Inc. (“Sigyn”, the “Company”, “we,” “us,” or “our”) is a development-stage company focused on addressing unmet needs in global health and biodefense. Sigyn Therapy™ is a broad-spectrum blood purification technology designed to reduce the presence of viral pathogens, bacterial toxins, and inflammatory mediators from the bloodstream.

 

Candidate treatment indications for Sigyn Therapy include endotoxemia and inflammation in End-Stage Renal Disease (ESRD) patients, Sepsis (leading cause of hospital deaths worldwide1), Community Acquired Pneumonia (a leading cause of death among infectious diseases2) and Emerging Bioterror and Pandemic threats.

 

Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have filed patent and trademark submissions related to a therapeutic system to enhance the delivery of cancer chemotherapy and reduce its toxicity.

 

Merger Transaction

 

On October 19, 2020, Reign Resources Corporation, completed a Share Exchange Agreement (the “Agreement”) with Sigyn Therapeutics, Inc., a private entity incorporated in the State of Delaware on October 19, 2019. Pursuant to the Share Exchange Agreement, we acquired 100% of the issued and outstanding shares of privately held Sigyn Therapeutics common stock in exchange for 75% of the fully paid and nonassessable shares of our common stock outstanding (the “Acquisition”). In conjunction with the transaction, we changed our name from Reign Resources Corporation to Sigyn Therapeutics, Inc. pursuant to an amendment to our articles of incorporation that was filed with the State of Delaware. Subsequently, our trading symbol was changed to SIGY. The Acquisition was treated as a “tax-free exchange” under Section 368 of the Internal Revenue Code of 1986 and resulted in the private Sigyn Therapeutics corporate entity becoming a wholly owned subsidiary known as Sigyn Medical Corporation. Upon the closing of the Acquisition, we appointed James A. Joyce and Craig P. Roberts to serve as members of our Board of Directors.

 

As of August 15, 2022, we had a total 37,295,813 shares issued and outstanding, of which 11,655,803 shares are held by non-affiliate shareholders.

 

Post-Merger Developments

 

Since the consummation of the Acquisition on October 19, 2020, we have advanced Sigyn Therapy from conceptual design through completion of in vitro studies that have quantified the reduction of relevant therapeutic targets from human blood plasma with small-scale versions of Sigyn Therapy. These include endotoxin (gram-negative bacterial toxin); peptidoglycan and lipoteichoic acid (gram-positive bacterial toxins); viral pathogens (including SARS-CoV-2); hepatic toxins (ammonia, bile acid, and bilirubin); and tumor necrosis factor alpha (TNF alpha), interleukin-1 beta (IL-1b), and interleukin 6 (IL-6), which are pro-inflammatory cytokines whose dysregulated production (the cytokine storm) precipitate sepsis and play a prominent role in each of our therapeutic opportunities.

 

Subsequent to these studies, we disclosed the completion of in vivo animal studies. In these studies, Sigyn Therapy was administered via standard dialysis machines utilizing conventional blood-tubing sets, for periods of up to six hours in eight (8) porcine (pig) subjects, each weighing approximately 40-45 kilograms. The studies were comprised of a pilot phase (two subjects), which evaluated the feasibility of the study protocol in the first-in-mammal use of Sigyn Therapy; and an expansion phase (six subjects) to further assess treatment feasibility and refine pre-treatment set-up and operating procedures. There were no serious adverse events reported in any of the treated animal subjects. Of the eight treatments, seven were administered for the entire six-hour treatment period. One treatment was halted early due to the observation of a clot in the device, which was believed to be the result of a procedural deviation in the pre-treatment set-up. Important criteria for treatment feasibility – including hemodynamic parameters, serum chemistries and hematologic measurements – were stable across all subjects.

 

The studies were conducted by a clinical team at Innovative BioTherapies, Inc. (“IBT”), under a contract with the University of Michigan to utilize animal care, associated institutional review oversight, as well as surgical suite facilities located within the North Campus Research Complex. The treatment protocol of the study was reviewed and approved by the University of Michigan Institutional Animal Care and Use Committee (IACUC).

 

The animal studies were conducted to correspond with FDA’s best practice guidance. The number of animals enrolled in our study and the amount of data collected was based on the ethical and least burdensome principles that underly the FDA goal of using the minimum number of animals necessary to generate valid scientific data to demonstrate reasonable feasibility and performance of a medical device prior to human study consideration. A porcine animal model is a generally accepted model for the study of extracorporeal blood purification devices intended to treat infectious disease and inflammatory disorders. Regardless of these factors, FDA may require that we conduct additional animal studies.

 

44
 

 

The data resulting from our in vivo and in vitro studies is being incorporated into an Investigational Device Exemption (IDE) that we are drafting for submission to the U.S. Food and Drug Administration (“FDA”) to support the potential initiation of a human feasibility study in End-Stage Renal Disease (ESRD) patients with endotoxemia and elevated inflammatory cytokine production. As per the study protocol, Sigyn Therapy is to be administered in combination with the regularly scheduled dialysis treatments of enrolled subjects. The primary study objective will be to evaluate the safety of Sigyn Therapy in health compromised ESRD patients. A secondary objective will be to quantify changes in circulating levels of endotoxin, tumor necrosis factor-αlpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) before and after each Sigyn Therapy administration. Endotoxin and excess TNF-α, IL-1β, and IL-6 production are commonly associated with each of our candidate treatment indications, including sepsis and community-acquired pneumonia.

 

Based on our previous experience in developing extracorporeal blood purification therapies, we believe that we have collected sufficient data to support first-in-human studies of Sigyn Therapy. In this regard, we plan to submit an IDE application to FDA related to the potential initiation of a human feasibility study during the 2023 calendar year. However, there is no assurance that FDA will approve the initiation of our feasibility study. Additionally, while we believe the data from our in vivo and in vitro studies provides support for our IDE submission, FDA may request that we conduct additional animal or pre-clinical studies prior to approving our IDE. Among our previous experiences in developing extracorporeal blood purification therapies, our CEO oversaw the development of the Aethlon Hemopurifier, a first-in-industry device that received an FDA “Breakthrough Device” designation for the treatment of life-threatening viruses and was awarded a second FDA “Breakthrough Device” designation related to the treatment of cancer.

 

Legal Proceedings

 

From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future. To the best our knowledge, none of our directors, officers or affiliates is involved in a legal proceeding adverse to our business or has a material interest adverse to our business.

 

Sigyn Therapy Mechanism of Action

 

We designed Sigyn Therapy to be a candidate to treat pathogen-associated inflammatory conditions that are life-threatening. To date, pre-clinical in vitro studies have quantified the reduction of viral pathogens, bacterial toxins, and inflammatory mediators from human blood plasma with small-scale versions of Sigyn Therapy. Such capabilities establish Sigyn Therapy as a candidate to treat pathogen-associated conditions that precipitate Sepsis, Community Acquired Pneumonia, Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease patients with endotoxemia and elevated inflammatory cytokine production.

 

To support widespread implementation, Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines already located in hospitals and clinics. To reduce the risk of blood clotting and hemolysis, the anticoagulant heparin is administered, which is the standard-of-care drug administered in dialysis and CRRT therapies. During animal studies conducted at the University of Michigan, Sigyn Therapy was deployed for use on a hemodialysis machine manufactured by Fresenius Medical Care, the global leader in the dialysis industry.

 

Incorporated within Sigyn Therapy is a “cocktail” of adsorbent components formulated to optimize the broad-spectrum reduction of therapeutic targets from the bloodstream. In the medical field, the term “cocktail” is a reference to the simultaneous administration of multiple drugs (a drug cocktail) with differing mechanisms of actions. While drug cocktails are emerging as potential mechanisms to treat cancer, they are life-saving countermeasures to treat HIV and Hepatitis-C viral infections. However, dosing of multi-drug agent cocktails is limited by toxicity and adverse events that can result from deleterious drug interactions.

 

Sigyn Therapy is not constrained by such limitations as active adsorbent components are maintained within Sigyn Therapy and not introduced into the body. As a result, we are able to incorporate a substantial quantity of adsorbent components to capture therapeutic targets outside of the body as they circulate through Sigyn Therapy. Each adsorbent component has differing capture characteristics that contribute to optimizing the potential of Sigyn Therapy to reduce the presence of pathogenic and inflammatory targets that precipitate the cytokine storm that underlies sepsis and other life-threatening inflammatory disorders.

 

The adsorbent components incorporated within Sigyn Therapy provide more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove circulating viruses, bacterial toxins, and inflammatory mediators. Beyond a potential capacity to reduce therapeutic targets from human blood plasma, we believe that Sigyn Therapy offers an efficient treatment methodology. Based on targeted blood flow rates of 350ml/min, a patient’s entire bloodstream can pass through Sigyn Therapy more than fifteen times during a single four-hour treatment period.

 

From a technical perspective, Sigyn Therapy is a 325mm long polycarbonate column that internally contains polyethersulphone hollow fibers that have porous walls with a median pore size of ~200 nanometers (nm). As blood flows into Sigyn Therapy, plasma and therapeutic targets below 200nm travel through the porous walls as a result of blood-side pressure. As the hollow fiber bundle within Sigyn Therapy creates a resistance to the flow of blood, a pressure drop is created along the length of the device such that the blood-side pressure is higher at the blood inlet and lower at the blood outlet. This allows for plasma and therapeutic targets to flow away from the blood and into the extra-lumen space (inside the polycarbonate shell, yet outside the hollow-fiber bundle) to interact with Sigyn Therapy’s adsorbent components in a low shear force environment. In the distal third of the fiber bundle, the pressure gradient is reversed, which allows for plasma to flow back through the fiber walls to be reconvened into the bloodstream without the presence of therapeutic targets that were captured or bound by adsorbent components housed in the extra-lumen space of Sigyn Therapy.

 

45
 

 

Overview of Candidate Treatment Indications

 

Based on data resulting from in vitro blood purification studies, our candidate treatment indications include, but are not limited to; pathogen-associated inflammatory conditions that precipitate Sepsis (leading cause of hospital deaths worldwide), Community Acquired Pneumonia (a leading cause of death among infectious diseases), Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease (ESRD) patients with endotoxemia and elevated inflammatory cytokine production. However, there is no assurance that human feasibility and pivotal studies will demonstrate Sigyn Therapy to be a safe and efficacious treatment for any treatment indications.

 

End-Stage Renal Disease, Endotoxemia and Inflammation

 

According to the United States Renal Data System (USRDS), more than 550,000 individuals suffer from end-stage renal disease (ESRD), which results in approximately 85 million kidney dialysis treatments being administered in the United States each year. Persistent inflammation is a hallmark feature of ESRD as reflected by the excess production of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), which contribute to increased all-cause mortality. ESRD inflammation also induces intestinal permeability, which allows endotoxin (gram-negative bacterial toxin) to translocate from the gut and into the bloodstream. Beyond fueling further inflammation, endotoxin is potent activator of sepsis, which can lead to multiple organ failure and ultimately death.

 

Sigyn Therapy establishes a candidate strategy to improve the health and quality-of-life of ESRD patients. Beyond its potential to reduce endotoxin, TNF-α, IL-1β, and IL-6 from human blood plasma, Sigyn Therapy can be administered in series with regularly scheduled dialysis therapy.

 

We are currently preparing an Investigational Device Exemption (IDE) for submission to the U.S. Food and Drug Administration (“FDA”) related to a human feasibility study of Sigyn Therapy in ESRD patients with endotoxemia and elevated inflammatory cytokine production. As per the study protocol, Sigyn Therapy will be administered in combination with the regularly scheduled dialysis treatments of enrolled subjects. The primary study objective will be to evaluate the safety of Sigyn Therapy in health compromised ESRD patients. A secondary objective is to quantify changes in circulating levels of endotoxin, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) before and after each Sigyn Therapy administration. Endotoxin and excess TNF-α, IL-1β, and IL-6 production are commonly associated with each of our candidate treatment indications, including sepsis and community-acquired pneumonia.

 

Sepsis

 

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In January of 2020, a report entitled; “Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study,” was published in the Journal Lancet. The publication reported 48.9 million cases of sepsis and 11 million deaths in 2017. In that same year, an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5-years old. The report included a reference that sepsis kills more people around the world than all forms of cancer combined. In the United States, sepsis was reported to be the most common cause of hospital deaths with an annual financial burden that exceeds $24 billion.

 

To date, more than 100 human studies have been conducted to evaluate the safety and efficacy of candidate drugs to treat sepsis. With one brief exception (Xigris, Eli Lilly), none of these studies resulted in a market cleared therapy.

 

46
 

 

As sepsis remains beyond the reach of single-target drugs, there is an emerging interest in multi-mechanism therapies that can target both inflammatory and pathogen associated targets. Sigyn Therapy addresses a broad-spectrum of pathogen sources and the resulting dysregulated cytokine production (the cytokine storm) that is the hallmark of sepsis. Additionally, we believe that inflammatory cytokine cargos transported by CytoVesicles may represent a novel, yet important therapeutic target.

 

Community Acquired Pneumonia

 

Community Acquired Pneumonia (CAP) represents a significant opportunity for Sigyn Therapy to reduce the occurrence of sepsis. CAP is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.

 

In the United States, more than 1.5 million individuals are hospitalized with CAP each year, resulting in an annual financial burden that exceeds $10 billion.

 

Statistically, a therapeutic strategy that reduced the incidence of CAP related sepsis and septic shock would save thousands of lives each year. In a study of 4,222 patients, the all-cause mortality for adult patients with CAP was reported to be 6.5% during hospitalization. However, the mortality of patients with CAP related sepsis and septic shock rose to 51% during hospitalization.

 

CAP is further complicated by the fact that the pathogen sources of CAP are identified in only 38% of patients, based on a study of 2,259 subjects whose pneumonia diagnosis was confirmed by chest x-ray. Of the source pathogens identified in the study, ninety seven percent (97%) were either viral or bacterial in origin.

 

To reduce the occurrence of CAP related sepsis and septic shock, Sigyn Therapy offers a broad-spectrum mechanism to reduce the circulating presence of viral pathogens and bacterial toxins before and if they are identified as the CAP pathogen source. Additionally, Sigyn Therapy may help to control the excess production of inflammatory cytokines (the cytokine storm) that precipitate sepsis and septic shock.

 

Emerging Pandemic Threats

 

Covid-19 affirmed the use of extracorporeal blood purification as a first-line countermeasures to treat an emerging pandemic threat not addressed with an approved drug or vaccine at the outset of an outbreak. On March 24, 2020, the U.S. Department of Health and Human Services (HHS) declared that the emergence of COVID-19 justified the Emergency-Use Authorization (EUA) of drugs, biological products, and medical devices to combat the pandemic. Within a month of this HHS declaration, FDA awarded an EUA to blood purification therapies from Terumo BCT, ExThera Medical Corporation, CytoSorbents, Inc., and Baxter Healthcare Corporation. In connection with these authorizations, FDA published a statement that blood purification devices may be effective at treating patients with confirmed COVID-19 by reducing various pathogens, cytokines, and other inflammatory mediators from the bloodstream.

 

Consistent with FDA’s statement, small-scale versions of Sigyn Therapy have been quantified to reduce the presence of various pathogens, cytokines, and other inflammatory mediators from human blood plasma during in vitro studies. As such, we believe that Sigyn Therapy could provide a candidate strategy to treat future pandemic outbreaks, which are increasingly being fueled by a confluence of global warming, urban crowding, and intercontinental travel.

 

Additionally, as a majority of infectious human viruses are not addressed with a corresponding drug or vaccine, there may be an ongoing need for blood purification technologies that offer to reduce the severity of infection and mitigate the excess production of inflammatory cytokines (the cytokine storm) associated with high mortality in non-pandemic viral infections. In this regard, we believe Sigyn Therapy aligns with HHS initiatives established through the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) that support the development of broad-spectrum medical countermeasures that can mitigate the impact of an emerging pandemic or bioterror threat, yet also have viability in established disease indications.

 

Candidate Pipeline Product

 

Beyond our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this regard, we have designed a therapeutic system to enhance the benefit of cancer chemotherapy. To support this endeavor, we disclosed on October 6, 2022, that a patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” had been filed with the United States Patent and Trademark Office (“USPTO”). On October 13, 2022, we subsequently disclosed that trademark applications to register ChemoPrepTM and ChemoPureTM were filed with the USPTO”.

 

Chemotherapeutic agents are the most commonly administered drugs to treat cancer, which is the second leading cause of death in the United States. Despite therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy. To overcome these challenges, our patent submission describes a therapeutic device system whose primary objective is to enhance tumor site delivery of chemotherapy and reduce its toxicity. A secondary objective of the system is to reduce treatment dosing without sacrificing patient benefit, or conversely increase chemotherapy dosing without added toxicity. In concert with these objectives, our candidate therapeutic system offers to inhibit the spread of cancer metastasis that can be induced by the administration of chemotherapy.

 

Our proposed chemotherapy enhancement system is comprised of two blood purification technologies. ChemoPrepTM, administered prior to chemotherapy to optimize tumor site delivery and improve the benefit of ChemoPureTM, which is deployed post-chemotherapy to reduce treatment toxicity and inhibit the potential spread of cancer metastasis.

 

47
 

 

To improve the delivery of chemotherapeutic agents, we designed ChemoPrepTM with an objective to reduce the bloodstream presence of tumor-derived extracellular vesicles or exosomes (Tumor-EXs) that diminish the efficacy of chemotherapy. As compared to non-cancer subjects, Tumor-EXs are highly concentrated in the bloodstream of those suffering from cancer. Tumor-EXs decoy and directly inhibit chemotherapeutic agents from reaching tumor cell targets. Tumor-EXs have also been reported to export chemotherapeutic agents out of cancer cells. Based on these factors, we believe the pre-chemo depletion of circulating Tumor-EXs could establish a novel, yet practical strategy to increase tumor-site saturation of chemotherapy, which in turn may permit for lower doses of chemotherapy to be administered without diminishing patient benefit.

 

ChemoPrepTM may also improve the performance of ChemoPureTM as a reduced bloodstream presence of Tumor-EXs, which are competitive binding and adsorption factors based on similar size and structural characteristics, would likely increase the efficiency of ChemoPureTM to reduce the presence of off-target chemotherapeutic agents that remain circulating in the bloodstream.

 

ChemoPureTM was designed to perform two critical functions after chemotherapy administration. To reduce treatment toxicity by lowering the bloodstream presence of chemotherapeutic agents that are not delivered to the target tumor site, and to reduce the circulating presence of chemotherapy-induced Tumor-EXs that may promote the spread of cancer metastases.

 

Unlike Sigyn TherapyTM, which is a candidate to treat life-threatening conditions that are not addressed with approved drug therapies, the intent of the ChemoPrepTM and ChemoPureTM is to enhance the delivery of market-cleared chemotherapeutic drugs and reduce their toxicity. Additionally, while Sigyn TherapyTM is a hollow-fiber based device designed for use on dialysis and continuous renal replacement machines, ChemoPrepTM and ChemoPureTM do not contain hollow-fibers and are intended for use on portable blood processing systems that can be located within the clinical sites where chemotherapy is administered. During treatment, the functionality of the blood processing system allows for patient blood plasma to flow through our devices, which contain formulations of adsorbent and binding components intended deplete Tumor-EXs and chemotherapeutic agents from the bloodstream.

 

In an in vitro study conducted by researchers at Innovative Biotherapies, we obtained pre-clinical insight that liposomal nanoparticles, commonly used to deliver chemotherapeutic agents, can be reduced from human blood plasma with a formulation of adsorbent components. In the study, liposome concentrations in human blood plasma were reduced by 92.5% after a two-hour interaction with the adsorbent components. Beyond providing initial support for our candidate strategy to remove liposomal drug agents, the study established the possibility that Tumor-EXs may also be reduced from blood plasma as liposomes have previously served as a research model system for isolating extracellular vesicles and exosomes based on a similarity of size and structural characteristics.

 

48
 

 

Recent Corporate Developments

 

December 2020 – Reported the first in vitro study results of Sigyn Therapy. The study reported the simultaneous reduction of endotoxin, a gram-negative bacterial toxin, and relevant pro-inflammatory cytokines from human blood plasma. The cytokines evaluated in the study were Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a).
   
January 2021 - Reported the results of an in vitro study that modeled the potential of Sigyn Therapy adsorbent components to reduce the presence of CytoVesicles (extracellular vesicles that transport inflammatory cargos in the bloodstream) from human blood plasma.
   
January 2021 - Appointed industry veteran Eric Lynam as Head of Clinical Affairs, with a mandate to oversee clinical studies of Sigyn Therapy.
   
April 2021 - Disclosed in vitro study observations that small-scale versions of Sigyn Therapy were quantified to reduce the presence of viral pathogens, including SARS-CoV-2 (COVID-19) from human blood plasma.
   
April 2021 - Appointed former Aethlon Medical executive Charlene Owen as Director of Operations.
   
July 2021 - Disclosed the completion of in vitro studies that quantified the reduction of hepatic toxins (ammonia, bile acid & bilirubin) from human blood plasma with small-scale versions of Sigyn Therapy.
   
July 2021 - Disclosed the completion of a first-in-mammal pilot animal study of Sigyn Therapy at the University of Michigan.
   
December 2021 - Reported that small-scale versions of Sigyn Therapy reduced the presence of gram-positive bacterial toxins from human blood plasma.
   
February 2022 - Reported the subsequent completion of an in vivo animal study of Sigyn Therapy at the University of Michigan.
   
March 2022 - Appointed Jeremy Ferrell, CPA, MBA as Chief Financial Officer.
   
March 2022 - Announced the appointments of two internationally recognized clinician researchers, Alexander S. Yevzlin, MD, FASN and H. David Humes, MD, to Sigyn Therapeutics’ Scientific Advisory Board.
   
March 2022 - Ajay Verma, MD, PhD, a recognized thought leader in the field of neurology joins the Scientific Advisory Board.
   
April 2022 - Donald J. Hillebrand, M.D., a recognized thought leader in the field of Hepatology and Liver Transplantation joins the Scientific Advisory Board.
   
August 2022 – The Company’s common stock commences trading on the OTCQB Venture Market.
   
October 2022

 

Announced the appointment of Richa Nand, B.S., J.D.; Jim Dorst, B.S., M.S.; and Christopher Wetzel, B.S., M.B.A. to our Board of Directors.
   
Patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” is submitted to the United States Patent and Trademark Office (“USPTO”).
   
Trademark applications to register ChemoPrepTM and ChemoPureTM are filed with the USPTO related to medical device products to enhance cancer therapies.

 

49
 

 

Marketing and Sales

 

At present, our primary focus is the clinical and regulatory advancement of Sigyn Therapy. As such, we do not market or sell any therapeutic products at this time. However, we plan to forge relationships with organizations that have established distribution channels into markets that may have a demand for Sigyn Therapy should it receive market clearance from FDA or other foreign regulatory agencies.

 

Intellectual Property

 

We own the intellectual property rights to pending royalty-free patents that have been assigned to us by our co-founders, James A. Joyce and Craig P. Roberts. We have also received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) related to the use of Sigyn Therapeutics, Sigyn Therapy, and the protection of our corporate logo. We plan to continually expand our intellectual property portfolio and protect trade secrets that are not the subject of patent submissions. However, there is no assurance that the claims of current pending and future patent applications will result in issued patents. Pending changes in patent law, it is anticipated that each patent that becomes issued will have an enforceable life that will extend for a period of 20 years from the initial patent filing date and will expire at the end of such 20 year terms.

 

At present, we own the rights to the following patents pending.

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - U.S. Application No.: 62/881,740; Filing Date: 2019-08-01 - Inventors: Joyce and Roberts

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - International Patent Application No.: PCT/US2020/044223; Filing Date: 2020-07-30 - Inventors: Joyce and Roberts

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - U.S. Patent Application No.: 16/943,436; Filing Date: 2020-07-30 - Inventors: Joyce and Roberts

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - EP No.: 20757445; Filing Date: 2022-01-24 - Inventors: Joyce and Roberts

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - CA No.: 3148773; Filing Date: 2022-01-25 - Inventors: Joyce and Roberts

 

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - JP No.: 2022-506670; Filing Date: 2022-01-31 - Inventors: Joyce and Roberts

 

EXTRA-LUMEN ADSORPTION OF VIRAL PATHOGENS FROM BLOOD U.S. Patent Application No.: 63/177,520; Filing Date: 2021-04-21 Inventor: James A. Joyce

 

SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY U.S. Patent Application No.: 63/410,764; Filing Date: 09/28/2022 Inventor: James A. Joyce

 

Government Regulation

 

In the United States, Sigyn Therapy is subject to regulation by the FDA. Should we seek to commercialize Sigyn Therapy outside the United States, we expect to face comparable international regulatory oversight. The U.S. regulatory jurisdiction for extracorporeal blood purification therapies is the Center for Devices and Radiological Health (“CDRH”), the FDA branch that oversees the market approval of medical devices.

 

Based on published CDRH guidance, we believe that Sigyn Therapy will be classified as a Class III medical device that is subject to a Pre-Market Approval (“PMA”) submission pathway. A PMA pathway requires extensive data, including but not limited to technical documents, preclinical studies, animal studies, human clinical trials, the establishment of Current Good Manufacturing Practices (“cGMPs”) standards and labeling that fulfills FDA’s requirement to demonstrate reasonable evidence of safety and effectiveness of a medical device product. However, as Sigyn Therapy does not emit electronic product radiation, it will not be subject to regulatory challenges associated with medical devices that emit electronic radiation.

 

The commercialization of medical devices in the United States requires either a prior 510(k) clearance, unless it is exempt, or a PMA from the FDA. Generally, if a new device has a predicate that is already on the market under a 510(k) clearance, the FDA will allow that new device to be marketed under a 510(k) clearance; otherwise, a premarket approval, or PMA, is required. Medical devices are classified into one of three classes; Class I, Class II or Class III which are determined by the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Class I devices are deemed to be low risk and are subject to the general controls of the Federal Food, Drug and Cosmetic Act, such as provisions that relate to: adulteration; misbranding; registration and listing; notification, including repair, replacement, or refund; records and reports; and good manufacturing practices. Most Class I devices are classified as exempt from pre-market notification under section 510(k) of the FD&C Act, and therefore may be commercially distributed without obtaining 510(k) clearance from the FDA. Class II devices are subject to both general controls and special controls to provide reasonable assurance of safety and effectiveness. Special controls include performance standards, post market surveillance, patient registries and guidance documents. A manufacturer may be required to submit to the FDA a pre-market notification requesting permission to commercially distribute some Class II devices. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III. A Class III device cannot be marketed in the United States unless the FDA approves the device after submission of a PMA. We believe that Sigyn Therapy will be classified as a Class III device and as such will be subject to a PMA submission and approval.

 

Should Sigyn Therapy receive market clearance from FDA, we would need to comply with applicable laws and regulations that govern the development, testing, manufacturing, labeling, marketing, storage, distribution, advertising and promotion, and post-marketing surveillance reporting for medical devices. Failure to comply with these applicable requirements may subject a device and/or its manufacturer to a variety of administrative sanctions, such as issuance of warning letters, import detentions, civil monetary penalties and/or judicial sanctions, such as product seizures, injunctions and criminal prosecution. Our failure to comply with any of these laws and regulations could have a material adverse effect on our operations.

 

The Pre-market Approval Pathway

 

A pre-market approval (PMA) application must be submitted to the FDA for Class III devices for which FDA requires a PMA. The PMA application process is much more demanding than the 510(k)-pre-market notification process. A PMA application must be supported by extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA’s satisfaction reasonable evidence of safety and effectiveness of the device.

 

After a PMA application is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive review and thus whether the FDA will file the application for review. The FDA has 180 days to review a filed PMA application, although the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device.

 

50
 

 

Although the FDA is not bound by the advisory panel decision, the panel’s recommendations are important to the FDA decision making process. In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation, or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA’s regulations.

 

Upon completion of the PMA review, the FDA may: (i) approve the PMA which authorizes commercial marketing with specific prescribing information for one or more indications, which can be more limited than those originally sought; (ii) issue an approvable letter which indicates the FDA’s belief that the PMA is approvable and states what additional information the FDA requires, or the post-approval commitments that must be agreed to prior to approval; (iii) issue a not approvable letter which outlines steps required for approval, but which are typically more onerous than those in an approvable letter, and may require additional clinical trials that are often expensive and time consuming and can delay approval for months or even years; or (iv) deny the application. If the FDA issues an approvable or not approvable letter, the applicant has 180 days to respond, after which the FDA’s review clock is reset.

 

Clinical Trials

 

Clinical trials are almost always required to support PMA market clearance and are sometimes required for 510(k) clearance. In the United States, for significant risk Class III devices, these trials require submission of an Investigational Device Exemption (IDE) application to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specific number of patients at specified study sites. During the trial, the sponsor must comply with the FDA’s IDE requirements for investigator selection, trial monitoring, reporting and record keeping. The investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of investigational devices and comply with all reporting and record keeping requirements. Clinical trials for Class III devices may not begin until the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical trial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involving subjects and which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety and welfare of human research subjects. The FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements. Even if a trial is completed, there is no assurance that clinical testing will demonstrate the safety and effectiveness of Sigyn Therapy or other pipeline devices.

 

Manufacturing and Procurement

 

We are advancing a manufacturing relationship with an FDA registered Contract Manufacturing Organization (CMO) to establish cGMPs compliant manufacturing to support human clinical studies and potential commercialization should we receive clearance to market Sigyn Therapy. We plan to establish manufacturing procedure specifications that define each stage of our manufacturing, inspection and testing processes and the control parameters or acceptance criteria that apply to each activity that result in the production of our technology.

 

We have also established relationships with industry vendors that provide components necessary to manufacture our device. Should the relationship with an industry vendor be interrupted or discontinued, we believe that alternate component suppliers can be identified to support the continued manufacturing of our product. However, delays related to interrupted or discontinued vendor relationships could adversely impact our business.

 

Research and Product Development

 

To date, we have outsourced our research and product development activities, which include the performance of in vitro blood plasma validation studies, animal studies, pre-cGMPs product assembly and manufacturing through third party organizations with experience in advancing extracorporeal blood purification technologies. Our pre-clinical in vitro blood plasma studies we each performed under an agreement with Innovative BioTherapies, Inc. (IBT) and our animal clinical studies were conducted by IBT team members through a contract with the University of Michigan to utilize animal care, associated institutional review oversight, as well as surgical suite facilities located within the North Campus Research Complex. While we maintain ownership rights to all study data collected by IBT, we do permit for IBT to publish or present the results of our contracted studies. At present, we do not have plans to build and staff our own research and product development facility.

 

Employees

 

As of the date of this prospectus, the Company had 5 employees and believes its relationships with its employees are good.

 

51
 

 

DESCRIPTION OF PROPERTY

 

Operating Lease

 

Our corporate address 2468 Historic Decatur Road, Suite 140, San Diego, California, 92106

 

On May 27, 2021, the Company entered into a sixty-three month lease for its corporate office at $5,955 per month commencing June 15, 2021 maturing September 30, 2026.

 

We believe that our existing facilities are adequate for our current needs and that we will be able to lease suitable additional or alternative space on commercially reasonable terms if and when we need it.

 

DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

 

Directors and Executive Officers

 

The following table sets forth the names, ages, and biographical information of each of our current directors and executive officers and the positions with the Company held by each person. Our executive officers are elected annually by the board of directors. The directors serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation or removal by the board of directors. Unless described below, there are no family relationships among any of the directors and officers.

 

Name   Age   Title
Jim Joyce   60   Chief Executive Officer and Chairman of the Board of Directors (“CEO”)
Craig Roberts   69   Chief Technology Officer and Director
Jeremy Ferrell (1)   52   Chief Financial Officer
Richa Nand (2)   49   Non-Employee Director
Jim Dorst (2)   69   Non-Employee Director
Christopher Wetzel (2)   47   Non-Employee Director

 

(1)Mr. Ferrell was hired as the Company’s Chief Financial Officer effective March 9, 2022.
  
(2)Ms. Nand, Mr. Dorst and Mr. Wetzel were appointed as Non-Executive Directors effective October 10, 2022.

 

Executive Officers

 

Jim Joyce. Mr. Joyce is a Co-founder of Sigyn Therapeutics and has served as Chairman and CEO of the Company since it was founded in 2019. He has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. Previously, Mr. Joyce was the founder of Exosome Sciences, Inc., where he served as Executive Chairman from 2011 to 2018. Mr. Joyce is also the founder, former Chairman and CEO of Aethlon Medical, a therapeutic device company that he navigated from a single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders.

 

While employed at Aethlon from 1999 to 2018, Mr. Joyce oversaw the development of the Aethlon Hemopurifier, the first therapeutic candidate to receive two “Breakthrough Device” designations from the FDA. Under his leadership, the Hemopurifier received FDA “Emergency Use Authorization” (EAU) approval to treat Ebola virus and additionally was cleared to treat Ebola by the German Government and Health Canada. Time Magazine named the Hemopurifier one of the “11 Most Remarkable Advances in Healthcare” and designated the device to its “Top 25 Best Inventions” award list.

 

During Mr. Joyce’s tenure, Aethlon won multiple Department of Defense (DOD) contract awards, a National Cancer Institute (NCI) contract award and grants from the National Institutes of Health (NIH). He also led the completion of approximately $100 million of equity financings and originated preclinical and clinical collaborations with more than twenty government and non-government institutes and organizations.

 

We believe Mr. Joyce’s service as our Chief Executive Officer, his extensive experience in therapeutic device technologies, his prior board service and his extensive public company background qualifies him to serve on our board of directors.

 

Craig Roberts. Mr. Roberts is an inventor of therapeutic device technologies, which includes a Percutaneous Adult Extracorporeal Membrane Oxygenation (ECMO) system that was licensed and subsequently sold to C.R. Bard. During the ongoing pandemic, ECMO has been broadly deployed to treat critically ill COVID-19 patients. Additionally, Mr. Roberts is the inventor of the IMPACT System, which received CE Mark clearance in the European Union and was subsequently registered in 32 countries and successfully deployed to treat cytokine storm related conditions, including sepsis, acute respiratory distress syndrome (ARDS), acute liver failure, severe pneumonia and H5N1 bird flu virus infection.

 

Mr. Roberts is a Co-founder of Sigyn Therapeutics and has been our Chief Technical Officer since it was founded in 2019. Prior to joining the Company, Mr. Roberts served as a consultant for Aethlon Medical, Inc. from 2016 to 2019. Prior to Aethlon, Mr. Roberts was a founder, Chief Technology Officer and Board Member of Hemolife Medical, Inc. We believe Mr. Roberts’s service as our Chief Technology Officer, his extensive experience with therapeutic device technologies and his previous service as board of medical device company qualifies him to serve on our board of directors.

 

52
 

 

Jeremy Ferrell. Mr. Ferrell has more than 25 years of finance and operations leadership experience, with expertise in venture capital; mergers and acquisitions; due diligence; initial public offerings; strategic alliance negotiation; and financial planning and reporting. Mr. Ferrell has served as our CFO since March 2022. Prior to joining the Company, Mr. Ferrell served as the CFO at Miku, Inc, from 2018 to 2022. Previously, he founded a Fractional CFO Services firm, where he served as CFO for various life sciences and technology companies, including Singular Genomics, Inc., Aspen Neuroscience, Inc., and Hyduro, Inc. Before that, he served as Corporate Controller for ecoATM, Inc., which was acquired by Outerwall, Inc. in 2013. Earlier in his career, Mr. Ferrell practiced as a certified public accountant. Mr. Ferrell received his Bachelor of Science degree in Accountancy from Liberty University and his Master of Business Administration degree in International Finance from the Thunderbird School of Global Management.

 

Non-Employee Directors

 

Richa Nand. Ms.Nand is a senior legal executive with more than 20 years of experience as an intellectual property (“IP”) attorney and strategic business advisor for biotechnology and medical device companies. Ms. Nand is the founder of Insight Patents (for which she has been a principal since 2014), a legal and consulting firm providing IP and transactional corporate services for the life sciences industry. Ms. Nand previously served as Vice President of Corporate Development and Legal at Bird Rock Bio – a Johnson & Johnson-backed biopharmaceutical company in San Diego – and Vice President of Intellectual Property and Licensing; Director of Business Development; and In-House Patent Counsel at Cytori Therapeutics. Prior to law school, she was a biomedical researcher at Cedars Sinai Medical Center in Beverly Hills, California. Ms. Nand received a Bachelor of Science degree in Microbiology and Molecular Genetics from the University of California, Los Angeles, and a Juris Doctor degree from Boston University School of Law. The Company believes Ms. Nand is qualified to sit on its Board due to her experience with medical device companies.

 

Jim Dorst. Mr. Dorst has more than 30 years of senior management experience in finance, operations, planning and business transactions at both private and public companies. He was most recently Director of Corporate Development at SYNNEX/Concentrix from July 2013 to January 2021, where he was primarily responsible for mergers and acquisitions. Mr. Dorst was previously Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”) at SpectraScience, Inc.; CFO of Aethlon Medical, Inc. and Vice President of Finance and Operations for Verdisoft Corporation. In addition, he previously served as Senior Vice President of Finance and Administration at SeeCommerce; CFO and COO of Omnis Technology Corp; and CFO and Senior Vice President of Information Technology at Savoir Technology Group, Inc. Mr. Dorst practiced as a Certified Public Accountant with Coopers & Lybrand (now PricewaterhouseCoopers LLP); and holds a Master of Science degree in Accounting and a Bachelor of Science degree in Finance from the University of Oregon. The Company believes Mr. Dorst is qualified to sit on its Board due to his longstanding involvement with public companies.

 

Christopher Wetzel. Mr. Wetzel has more than 25 years of leadership experience in various aspects of the healthcare delivery system and since 2004, has served as Chief Executive Officer for the Surgery Center at Hamilton in New Jersey. His career has focused on building organizations, increasing operational efficiency, increasing profitability, maximizing revenue, and managing change in the complex and high-growth healthcare environment. Mr. Wetzel applied his broad background in strategy, finance, and operations to guide various entities starting new ventures, entering new markets, and reengineering business processes. He is a long-term investor in the extracorporeal therapy space. Mr. Wetzel received a Master of Business Administration degree in Healthcare Management and a Bachelor of Science degree in Nursing from Thomas Jefferson University (formerly Philadelphia University). The Company believes Mr. Wetzel is qualified to sit on its Board due to his decades of experience in the healthcare delivery system.

 

Conflicts of Interest

 

Certain potential conflicts of interest are inherent in the relationships between our officers and directors and us.

 

From time to time, one or more of our affiliates may form or hold an ownership interest in and/or manage other businesses both related and unrelated to the type of business that we own and operate. These persons expect to continue to form, hold an ownership inter